

2021 NATIONAL HEALTH RESEARCH FORUM

STRAIGHT TALK: FIGHTING HEALTH THREATS FASTER



BIOGRAPHIES

DANA ACTON, Director, Science Policy and Legislative Affairs, American Association for Cancer Research (AACR)

Dana previously worked for more than a decade in the office of Rep. Nita M. Lowey, Chairwoman of the House Appropriations Committee. From 2015-2020, she served as Legislative Director and the Chairwoman's point person on the Subcommittees on Agriculture and Labor, Health and Human Services, and Education, handling investments in medical research and public health. Dana is a graduate of American University and Rutgers School of Law, and was a Henry J. Raimondo Legislative Fellow at the Eagleton Institute of Politics.

PETER C. ADAMSON, MD, Global Head, Oncology Development and Pediatric Innovation, Sanofi

Peter C. Adamson, MD is Global Development Therapeutic Area Head, Oncology and Pediatric Innovation at Sanofi. Based in Cambridge, MA, Dr. Adamson leads Global Development efforts to build and deliver an innovative and sustainable portfolio of transformative medicines for patients with cancer. He is also working with leaders across Sanofi's therapeutic areas to further pediatric drug development efforts.

Prior to joining Sanofi, Dr. Adamson was Professor of Pediatrics and Pharmacology at the Perelman School of Medicine of the University of Pennsylvania and held the Alan R. Cohen Endowed Chair in Pediatrics at Children's Hospital of Philadelphia (CHOP). Most recently, Peter served as Chair of the Children's Oncology Group (COG), a National Cancer Institute supported international consortium of more than 220 childhood centers.

Dr. Adamson, currently Emeritus Professor of Pediatrics and Pharmacology at the Perelman School of Medicine, is Board Certified in Hematology/Oncology and Clinical Pharmacology. He was appointed by President Obama to, and continues to serve on, the National Cancer Advisory Board (NCAB), and also served on the Blue-Ribbon Panel for the Beau Biden National Cancer Moonshot Initiative. Dr. Adamson received his undergraduate degree from Wesleyan University and his medical degree from Cornell University Medical College. He performed his residency at Children's Hospital of Philadelphia and his fellowship in the Pediatric Oncology Branch of the National Cancer Institute.

SALVATORE AIELLO, MD/PhD Candidate, Rosalind Franklin University of Medicine & Science

Salvatore Aiello graduated from the University of Michigan in 2014 with a double major in Biomolecular Sciences and Spanish and a minor in Writing. He has a master's degree in Biomedical Sciences from Rosalind Franklin University, where he is currently a fifth year MD/PhD candidate. He is researching resuscitation science methodologies, such as ventricular fibrillation waveform analysis, to improve out-of-hospital cardiac arrest survival.

JEFF ALLEN, PhD, President and CEO, Friends of Cancer Research

Jeff Allen, PhD serves as the President and CEO of Friends of Cancer Research (Friends). During the past 20 years, Friends has been instrumental in the creation and implementation of policies ensuring patients receive the best treatments in the fastest and safest way possible. As a thought leader on many issues related to the Food and Drug Administration, regulatory strategy and healthcare policy, he is regularly published in prestigious medical journals and policy publications, and has contributed his expertise to the legislative process on multiple occasions. Recent Friends initiatives include the establishment of the Breakthrough Therapies designation and the development of the Lung Cancer Master Protocol, a unique partnership that will accelerate and optimize clinical trial conduct for new drugs. Dr. Allen received his PhD in cell and molecular biology from Georgetown University, and holds a Bachelors of Science in Biology from Bowling Green State University.

ELIZABETH DODDS ASHLEY, PharmD, MHS, FCCP, BCPS, Associate Professor of Medicine, Division of Infectious Diseases & International Health; Operations Director, DASON, Duke Center for Antimicrobial Stewardship and Infection Prevention

Elizabeth S. Dodds Ashley, PharmD, MHS, is an Associate Professor of Medicine and Director of Operations for the Duke Antimicrobial Stewardship Outreach Network (DASON) based at Duke University. She has been an active antimicrobial stewardship pharmacist for more than 15 years. Her work and research in stewardship span a variety of patient care settings including large academic medical centers, community hospitals and long term care facilities. She has served as a member of the Antimicrobial Resistance Working Group at the Centers for Disease Control, and an expert panel member of the Transatlantic Taskforce for Antimicrobial Resistance among other appointments. She is a current liaison member and first pharmacist on the Presidential Advisory Council on Combating Antibiotic-Resistant Bacteria (PACCARB) representing SIDP. She is actively involved in several professional societies engaged in stewardship. including SHEA and SIDP where she recently served as President.

JULIA BEAVER, MD, Chief of Medical Oncology, Oncology Center of Excellence, FDA; Deputy Director (Acting), Office of Oncologic Diseases, Center for Drug Evaluation and Research, FDA

Dr. Julia A. Beaver is the Chief of Medical Oncology in the Oncology Center of Excellence at the U.S. Food and Drug Administration (FDA) and Deputy Director (acting) in the Office of Oncologic Diseases in the Center for Drug Evaluation and Research at FDA. She was previously the Director of the Division of Oncology 1. Prior to serving as Division Director, she was Breast Cancer Team Leader and then Supervisory Associate Division Director. Through her time at FDA, she has spearheaded the authorship of multiple FDA Guidances for Industry including guidance related to expansion of eligibility criteria, male breast cancer, placebos and blinding, and metastasis-free survival. Dr. Beaver has also published multiple regulatory research projects and co-leads the OOD/OBP Next Generation Sequencing Translational Research Laboratory. She serves on the Liquid Biopsy Blood Profiling Atlas in Cancer (Blood-PAC) committee and has particular expertise in Precision Oncology. Dr. Beaver also is an Assistant Professor of Oncology, part-time, at Johns Hopkins University where she is a member of the Johns Hopkins Breast Cancer Group. Dr. Beaver graduated *magna cum laude* from Princeton University and then earned her medical degree from the University of Pennsylvania School of Medicine. She completed a residency in Internal Medicine at Johns Hopkins University School of Medicine, followed by a fellowship in Medical Oncology at The Johns Hopkins Sidney Kimmel Cancer Center.

JOEL L. BEETSCH, PhD, Vice President, Corporate Affairs, Eisai, Inc.

Joel Beetsch currently holds the position of Vice President of Corporate Affairs at Eisai Incorporated (USA). In this position, Dr. Beetsch leads the U.S. efforts around strategic Communications, Government Affairs, Public Policy, Patient Advocacy, and Corporate Philanthropy. Using a highly collaborative approach across both internal and external stakeholders, Joel and his team will execute a coordinated patient-focused Eisai US Corporate strategy working with multiple patient, provider, payer, and policy stakeholders and organizations to foster safe and effective solutions to healthcare challenges. These efforts drive the assurance that patient access to healthcare solutions and medical innovation are valued and advanced. The Corporate Affairs team is poised to impact and shape the healthcare environment through cross-functional collaboration, strong partnerships with an array of influential external stakeholders, and a never-ending commitment to improve the lives of patients.

During his 20-year tenure in the biopharmaceutical industry, Dr. Beetsch has held several Medical and Corporate Affairs positions. Joel has professional interests in patient-focused care coordination, health policy, and the use of health information technology. Joel serves as the co-chairperson for the steering committee of the Susan G. Komen Big Data for Patients (BD4P) initiative and is engaged with the Clinical Trials Transformation Initiative (CTTI) efforts to connect patients and patient groups to the research and development process. Joel also serves as the President of the National Advisory Board for Family Reach, a non-profit organization dedicated to alleviating the financial burden of cancer.

Dr. Beetsch earned his Doctorate in Neurobiology/Biochemistry from the Boonshoft School of Medicine at Wright State University and further training at the Washington University School of Medicine. Joel lives in Mendham, New Jersey with his wife and two daughters.

STEFANO BERTUZZI, PhD, MPH, CEO, American Society for Microbiology

Dr. Stefano Bertuzzi is the Chief Executive Officer of the American Society for Microbiology (ASM), one of the largest life sciences professional societies in the world, with more than 30,000 members and in-country health activities in more than 80 countries. Its mission is to promote and advance microbial sciences. Dr. Bertuzzi served as a senior scientific executive at the National Institutes of Health (NIH), where he advised the NIH Director on a wide range of science policy matters. Most recently, he's led ASM's efforts to address the SARS-CoV-2 pandemic, pushing for a robust federal response and supporting clinical microbiologists on the frontlines through advocacy and policy change. He's had editorials published in the New York Times and mBio addressing diagnostic testing roadblocks and emphasizing the role of microbiologists and other scientists in supporting the clinical and public health laboratory infrastructure and workforce.

Dr. Bertuzzi holds a Master's degree in Public Health at the Johns Hopkins Bloomberg School of Public Health, and a Ph.D. in Molecular Biotechnology from the Catholic University in Italy. In addition to authoring numerous research publications, editorials, and science policy pieces in top journals, he's also a fellow of the prestigious Aspen Institute. Most recently, the President of the Italian Republic bestowed upon Dr. Bertuzzi the title of Knight of the Order of the Star of Italy, one of the highest honors in the Italian Republic.

JILL BIDEN, EdD, First Lady of the United States

Jill Biden, EdD, is the First Lady of the United States, a community college educator, and bestselling author. Dr. Biden also served as Second Lady of the United States from 2009–2017. Jill Biden taught English at Rockford Center psychiatric hospital while also pursuing a Master of Arts in English from Villanova University. In 1993, she accepted a job at Delaware Technical Community College. In 2007, she received a Doctor of Education (EdD) in educational leadership from the University of Delaware.

When Joe Biden became Vice President and the Bidens moved to Washington, DC, Dr. Biden continued her career at Northern Virginia Community College, teaching throughout their eight years in office. As Second Lady, Dr. Biden focused on advocating for community colleges, military families, and the education of women and girls around the world.

As the Obama-Biden Administration focused on recovering from the 2008 economic recession, Dr. Biden worked to underscore the critical role of community colleges in the nation's economy. She hosted the first-ever White House Summit on Community Colleges with President Obama and led the Community College to Career Bus Tour to highlight industry partnerships between community colleges and employers. She also became the honorary chair of the College Promise National Advisory Board, leading the effort to make community colleges free for hard-working students. Dr. Biden has been a longtime advocate for military families. As Second Lady, she launched Joining Forces with First Lady Michelle Obama, an initiative to support service members, veterans, their families, caregivers, and survivors.

Dr. Biden's advocacy for more cancer education and prevention began in 1993, when four of her friends were diagnosed with breast cancer. Following that year, she launched the Biden Breast Health Initiative to educate Delaware high school girls about the importance of early detection. After Dr. Biden and then-Vice President

Joe Biden lost their son Beau to brain cancer in 2015, they helped push for a national commitment to ending cancer as we know it through the White House Cancer Moonshot.

As First Lady, Dr. Biden continues her work for education, military families, and fighting cancer. She is a professor of writing at Northern Virginia Community College.

ALBERT BOURLA, DVM, PhD, Chairman and CEO, Pfizer Inc

Albert Bourla became Chief Executive Officer on January 1, 2019. In his previous role, Albert was Pfizer's Chief Operating Officer (COO), overseeing the company's commercial strategy, manufacturing and global product development functions. Prior to being named COO, Albert was the Group President of Pfizer Innovative Health, responsible for the Inflammation & Immunology, Internal Medicine, Oncology, Rare Disease, Vaccines and Consumer Healthcare business groups. He also created the Patient and Health Impact group, dedicated to developing solutions for increasing patient access, demonstrating the value of our innovations and ensuring broader business model innovation.

Albert has more than 25 years of experience with Pfizer and has held a number of senior global positions across a range of markets and disciplines, including Group President of Pfizer's Global Vaccines, Oncology and Consumer Healthcare business and President and General Manager of Pfizer's Established Products business.

Albert joined Pfizer's Animal Health Division in 1993 as Technical Director of Greece. He held positions of increasing responsibility across Europe before moving to Pfizer Global Headquarters in New York in 2001 to assume the role of U.S. Group Marketing Director for Animal Health. In 2004, he became Vice President of Business Development and New Products Marketing, supervising Pfizer Animal Health global licensing and acquisition activities, as well as the unit's R&D portfolio. In 2006, he was appointed Area President of Europe, Africa and Middle East, and in 2009, he assumed additional responsibilities for Asia and Pacific.

Albert is a Doctor of Veterinary Medicine and holds a PhD in the Biotechnology of Reproduction from the Veterinary School of Aristotle University. Albert is a member of the Board of Directors of Pfizer Inc., the Pfizer Foundation, the Partnership for New York City and Catalyst.

JOY BUIE, PhD, MSCR, BSN, RN, Associate Director of Research, Lupus Foundation of America

Dr. Buie is the Associate Director of Research at the Lupus Foundation of America. She has a PhD in Immunology and is a registered nurse. Dr. Buie has a unique perspective on autoimmune disease as she is both a patient, scientist and a licensed healthcare professional. At the Lupus Foundation of America, Dr. Buie's current work focuses on the Health Disparities Study where professionals and patients from academia, healthcare, industry and the policy sectors are working together to identify the most pervasive social determinants of health leading to poorer outcomes in diverse populations living with lupus. She also co-leads the RAY Registry, a database specifically designed to capture information about lupus patients for better drug development and intervention design. Lastly Dr. Buie is responsible for overseeing the LFA's global research initiative designed for Addressing Lupus Pillars for Health Advancement (ALPHA). This work seeks to enhance

clinical care, drug development and access to care in all patients living with lupus. Prior to joining the LFA, Dr. Buie was an NINDS NIH-funded investigator where her work focused on health disparities in stroke.

JESSICA BYLANDER, Senior Editor and Correspondent, Health Affairs

Jessica Bylander is a senior editor and correspondent at Health Affairs, and edits the journal's "Narrative Matters" section of health policy narratives. She is one of the hosts of Health Affairs' This Week podcast, and is the editor of "Narrative Matters: Writing to Change the Health Care System" (second edition, Johns Hopkins University Press, 2020). At Health Affairs' parent company Project HOPE, she co-leads the Diversity, Equity, and Inclusion Council. She received a 2017 Association of Health Care Journalists Reporting Fellowship on Health Care Performance, and completed a science writing residency at Johns Hopkins University. Previously she covered the medical device industry for "The Gray Sheet." She studied journalism at Northwestern University, creative writing at Johns Hopkins University, and is studying public health at the University of Colorado, Anschutz Medical Campus.

ROBERT M. CALIFF, MD, MACC, Head of Clinical Policy and Strategy, Verily and Google Health; Adjunct Professor, Duke University and Stanford University; Former FDA Deputy Commissioner

Robert M. Califf, MD, MACC, is the Head of Clinical Policy and Strategy for Verily and Google Health. Prior to this, Dr. Califf was vice chancellor for health data science for the Duke University School of Medicine; director of Duke Forge, Duke's center for health data science; and Donald F. Fortin, MD, Professor of Cardiology. He served as Deputy Commissioner for Medical Products and Tobacco in the U.S. Food and Drug Administration (FDA) from 2015-2016, and as Commissioner of Food and Drugs from 2016-2017. A nationally and internationally recognized leader in cardiovascular medicine, health outcomes research, healthcare quality, and clinical research, Dr. Califf is a graduate of Duke University School of Medicine. Dr. Califf was the founding director of the Duke Clinical Research Institute and is one of the most frequently cited authors in biomedical science.

JOHN CARPTEN, PhD, Professor and Chair, Department of Translational Genomics; Director, Institute for Translational Genomics, Keck School of Medicine, University of Southern California

Dr. Carpten currently serves as Professor and Chair for the Department of Translational Genomics, and Director of the Institute for Translational Genomics, Keck School of Medicine, University of Southern California, Los Angeles, CA. He received his PhD in Molecular, Cellular and Developmental Biology from the Ohio State University and completed his postdoctoral fellowship at the National Human Genome Research Institute, Bethesda, MD. Prior to his current appointment at USC, he served as Professor and Deputy Director of Basic Sciences at the Translational Genomics Research Institute (TGen), Phoenix, AZ. Dr. Carpten's expertise spans a very broad range of research disciplines including germline genetics, tumor profiling, cancer cell biology, functional genomics, and health disparities. The primary goal of Dr. Carpten's research program is to discover molecular alterations in cancer and to translate these findings into new approaches for prevention, diagnosis and treatment. In support of this goal, his program is actively involved in the development and application of cutting edge technologies and novel bioinformatics approaches for discovery research. His work has impacted

our understanding of a variety of cancer types including prostate cancer, breast cancer, colon cancer, brain cancer, multiple myeloma, and pediatric cancers. Dr. Carpten has co-authored over 200 peer reviewed publications in scientific journals that include Science, Nature, Nature Genetics, Cancer Cell, Cancer Research, Molecular Cancer Therapeutics, and the New England Journal of Medicine. He was named a Science Trailblazer by Spectrum Magazine in 2006, and was awarded Susan G. Komen Distinguished Lectureship on the Science of Cancer Health Disparities in 2014 for his untiring work in ensuring that all people are equally represented in science and innovative healthcare. Dr. Carpten was also awarded the 2018 AACR MICR Jane Cooke Wright Lectureship for his outstanding research in cancer disparities and his efforts in developing the careers of minority scientists. In 2019, he served as Program Committee Chair for the AACR Annual Conference in Atlanta, GA, which included over 21,500 international participants. In 2021 he was inducted into the AACR Fellows of the Academy. He also currently serves as a member of the National Cancer Institute Board of Scientific Counselors and is a member of the scientific advisory board for Break Through Cancer.

THE HONORABLE MICHAEL N. CASTLE, Chair Emeritus, Research!America; Governor of Delaware, 1985-1992, U.S. Representative, 1993-2011

Gov. Mike Castle, Chair Emeritus of Research!America's Board of Directors, is a former two-term Governor, nine-term U.S. Congressman, Lieutenant Governor, Deputy Attorney General and State Senator, and partner in DLA Piper's Government Affairs practice. Governor Castle has always held a deep interest in financial services, health care and energy, and throughout his public life he has worked across party lines, building bridges and forming coalitions to find pragmatic, bipartisan solutions to some of the most pressing problems facing the country. His extensive state and federal experience provides a unique understanding on a wide array of issues faced by businesses that are dealing with federal laws and regulations, are incorporated in Delaware or dealing with Delaware business entities. During his nine terms as Delaware's sole member in the House of Representatives, Governor Castle served on the House Financial Services Committee, which has jurisdiction over the banking, securities and insurance industries, where he chaired the Subcommittee on Domestic and Monetary Policy and dealt with issues which directly affect the financial services industry and consumers.

JANINE AUSTIN CLAYTON, MD, FARVO, NIH Associate Director for Research on Women's Health; Director, NIH Office of Research on Women's Health

Janine Austin Clayton, MD, Associate Director for Research on Women's Health and Director of the Office of Research on Women's Health (ORWH) at the National Institutes of Health (NIH), is the architect of the NIH policy requiring scientists to consider sex as a biological variable across the research spectrum. This policy is part of NIH's initiative to enhance reproducibility through rigor and transparency. As co-chair of the NIH Working Group on Women in Biomedical Careers with NIH Director Dr. Francis Collins, Dr. Clayton also leads NIH's efforts to advance women in science careers. In 2021, Dr. Clayton was elected to the Board of Directors of the American Association for the Advancement of Science (AAAS).

Prior to joining the ORWH, Dr. Clayton was the Deputy Clinical Director of the National Eye Institute (NEI) for seven years. A board-certified ophthalmologist, Dr. Clayton's research interests include autoimmune ocular diseases and the role of sex and gender in health and disease. She is the author of more than 120 scientific publications, journal articles, and book chapters.

Dr. Clayton, a native Washingtonian, received her undergraduate degree with honors from Johns Hopkins University and her medical degree from Howard University College of Medicine. She completed a residency in ophthalmology at the Medical College of Virginia. Dr. Clayton completed fellowship training in cornea and external disease at the Wilmer Eye Institute at Johns Hopkins Hospital and in uveitis and ocular immunology at NEI.

Dr. Clayton has received numerous awards, including the Senior Achievement Award from the Board of Trustees of the American Academy of Ophthalmology in 2008 and the European Uveitis Patient Interest Association Clinical Uveitis Research Award in 2010. She was selected as a 2010 Silver Fellow by the Association for Research in Vision and Ophthalmology. In 2015, she was awarded the American Medical Women's Association Lila A. Wallis Women's Health Award and the Wenger Award for Excellence in Public Service. Dr. Clayton was granted the Bernadine Healy Award for Visionary Leadership in Women's Health in 2016. She was also selected as an honoree for the Woman's Day Red Dress Awards and the American Medical Association's Dr. Nathan Davis Awards for Outstanding Government Service in 2017.

MIKE COBURN, Executive Vice President and Chief Operating Officer, Research!America

Mike Coburn is Executive Vice President and Chief Operating Officer of Research!America. Throughout his more than 30 years serving the nonprofit sector, his focus on optimizing organizational performance through strong governance, sound financial management, innovative resource development and passionate advocacy has blazed a track record of success with prominent mission-based organizations. Mike previously served as Chief Operating Officer for The Arc of the United States, the nation's leading advocacy organization for people with intellectual and developmental disabilities. Coburn was previously President and CEO of the Tuberous Sclerosis Alliance. Under his leadership, the organization formed innovative scientific and clinical collaborations to accelerate scientific discovery and enhance patient care for individuals living with tuberous sclerosis complex. Prior executive experience includes leadership positions with national nonprofit organizations.

FRANCIS S. COLLINS, MD, PhD, Director, National Institutes of Health

Francis S. Collins, MD, PhD, was appointed the 16th Director of the National Institutes of Health (NIH) by President Barack Obama and confirmed by the Senate. He was sworn in on August 17, 2009. In 2017, President Donald Trump asked Dr. Collins to continue to serve as the NIH Director. President Joe Biden did the same in 2021. Dr. Collins is the only Presidentially-appointed NIH Director to serve more than one administration. In this role, Dr. Collins oversees the work of the largest supporter of biomedical research in the world, spanning the spectrum from basic to clinical research.

Dr. Collins is a physician-geneticist noted for his landmark discoveries of disease genes and his leadership of the international Human Genome Project, which culminated in April 2003 with the completion of a finished sequence of the human DNA instruction book. He served as director of the National Human Genome Research Institute at NIH from 1993-2008.

Dr. Collins is an elected member of both the National Academy of Medicine and the National Academy of Sciences, was awarded the Presidential Medal of Freedom in November 2007, and received the National Medal of Science in 2009. In 2020, he was elected as a Foreign Member of the Royal Society (UK) and was also named the 50th winner of the Templeton Prize, which celebrates scientific and spiritual curiosity.

ALEXANDRA COLÓN-RODRIGUEZ, PhD, Postdoctoral Scientist, Neurobiology, Physiology, and Behavior, University of California Davis

Dr. Alexandra Colón-Rodríguez is neurotoxicologist postdoctoral research scientist in the Department of Neurobiology, Physiology and Behavior at the University of California, Davis. She leads the science communication training program for faculty and conducts neuroscience research focused on parental care behavior.

JACQUELINE CORRIGAN-CURAY, JD, MD, Principal Deputy Center Director, Center for Drug Evaluation and Research, FDA

Jacqueline Corrigan-Curay, J.D., MD, is the Principal Deputy Center Director in FDA's Center for Drug Evaluation and Research (CDER). Most recently, she served as the Acting Center Deputy Director for Operations, directing center and agency-level priority and initiative programs and leading GDUFA III reauthorization negotiations. Previously, Dr. Corrigan-Curay was director of CDER's Office of Medical Policy (OMP). In that role, she led the development, coordination, and implementation of medical policy programs and strategic initiatives. She worked collaboratively with other CDER program areas, FDA centers, and stakeholders on enhancing policies to improve drug development and regulatory review processes.

Dr. Corrigan-Curay brings to the position a unique legal, scientific policy, and clinical background with expertise in risk and scientific assessment, and clinical trial design and oversight. Before joining FDA, she served as supervisory medical officer with the Immediate Office of the Director, National Heart, Lung and Blood Institute (NHLBI) at the National Institutes of Health (NIH). She also served in director and acting director roles with the Office of Biotechnology Activities (OBA), Office of Science Policy at NIH, where she was executive secretary of the NIH Recombinant DNA Advisory Committee. She has held positions as an attending physician with the VA Medical Center, a policy analyst with the Congressional Office of Technology Assessment, and as a practicing attorney in Washington, D.C. Dr. Corrigan-Curay earned her law degree from Harvard Law School, her medical degree from University of Maryland School of Medicine, and a bachelor's degree in history of science from Harvard/Radcliffe College in Cambridge, MA. She completed her training in internal medicine at Georgetown University Medical Center, where she also served as a clinical assistant professor of medicine. She has continued to practice internal medicine part-time at the Veterans Affairs Medical Center in Washington, D.C.

PAIGE WINFIELD CUNNINGHAM, Editor, *The Health 202*, *The Washington Post*

Paige Winfield Cunningham is editor of *The Health 202* and several of *The Post's* other policy and politics newsletters. She previously authored *Health 202* for four and a half years, covering the biggest health care storylines in Washington and around the nation, including the 2017 Obamacare repeal-and-replace effort, the Trump administration's efforts to reshape health insurance, the opioid epidemic, the Democratic debates over

Medicare-for-all and the coronavirus pandemic. Cunningham regularly anchors Post Live events, and has interviewed top health influencers such as NIAID Director Anthony Fauci, Surgeon General Vivek Murthy, former HHS secretary Alex Azar and former CMS administrator Seema Verma.

Cunningham started her reporting career in the Chicago area, covering county government for the Naperville Sun. She lives in Alexandria, Virginia, with her husband and three children.

THE HONORABLE DIANA DEGETTE, U.S. Representative (D-CO-01)

U.S. Rep. Diana DeGette (D-CO) represents Colorado's 1st Congressional District in the U.S. House of Representatives and serves as chair of the House Energy and Commerce Committee's Oversight and Investigations panel. Prior to serving in the U.S. House, DeGette served two terms in the Colorado House of Representatives, from 1992 – 1996, before she was first elected to Congress in 1996.

While in Congress, DeGette has become a leading voice on health care policy and played a key role in drafting the Affordable Care Act. Now, as chair of the House Energy and Commerce Oversight and Investigations panel - which oversees the nation's health agencies - DeGette has helped lead the charge in overseeing the federal government's response to the COVID-19 pandemic.

DeGette is widely regarded for her work as the co-author of the 21st Century Cures Act, a landmark piece of legislation that has modernized how our nation researches and develops new cures and treatments for some of the world's most difficult diseases. She and the bill's other co-author, U.S. Rep. Fred Upton (R-MI), recently unveiled the framework for their newest piece of health care legislation, known as Cures 2.0, which seeks to build upon the tremendous success they achieved with their first bill.

ELLIE DEHONEY, Vice President of Policy and Advocacy, Research!America

Ellie has been Vice President of Policy and Advocacy since March of 2011. Prior to joining Research!America, Ellie served as a Legislative Director in the office of Senator Sherrod Brown. Ellie also served as the legislative director for Brown in the House of Representatives, where she maintained lead responsibility for work related to his role as Ranking Member of the Energy and Commerce Committee's Health Subcommittee. Before joining Brown's staff, Ellie served as a Legislative Assistant for former Senate Minority Leader Tom Daschle.

SARAH GRACE DENNIS-LITTLE, PhD, Postdoctoral Scholar, Department of Surgery, Medical University of South Carolina

Sarah Grace Dennis-Little, PhD, obtained her Bachelors of Science in Biomedical Engineering in 2013 from Tulane University and went on to receive her PhD in Bioengineering from Clemson University in 2018. She is now a postdoctoral scholar at the Medical University of South Carolina, Department of Surgery and is also pursuing an MBA.

THE HONORABLE CHARLIE DENT, Executive Director & Vice President, The Aspen Institute; Senior Policy Advisor, DLA Piper LLP; U.S. Representative, 2005-2018

Congressman Charlie Dent is Executive Director and Vice President of the Aspen Institute Congressional Program, where he leads bipartisan, bicameral policy education programs for sitting members of Congress. In addition to his role at the Aspen Institute, Congressman Dent is a Political Commentator for CNN, a Senior Policy Advisor to the global law firm, DLA Piper, and a Distinguished Advisor for Pew Charitable Trusts, and a former Visiting Fellow for the University of Pennsylvania (UPENN), Perry World House.

Prior to those positions, Congressman Dent served 7 terms in the U.S. House of Representatives representing the 15th Congressional District of Pennsylvania. During his time in Congress, Congressman Dent distinguished himself as a strong, independent leader who is well respected on both sides of the aisle. Congressman Dent was a senior member of the House Appropriations Committee where he chaired the Subcommittee on Military Construction, Veterans Affairs and Related Agencies. Additionally, he served as the Chairman of the House Committee on Ethics from 2015 – 2017. In addition to his role as a senior Appropriator, Congressman Dent was the co-chair of the Tuesday Group, a caucus of more than 50 center-right Republicans, where he played an important role in many of the most challenging policy and political issues confronted by Congress. Congressman Dent was a member of the Speaker of the House's weekly cross section lunch and was a member of the Majority Leader's Chairman's Table.

Before his time in the U.S. House of Representatives, Congressman Dent served for 6 years in the Pennsylvania State Senate and 8 years in the Pennsylvania House of Representatives. Congressman Dent holds a Bachelor of Arts in Foreign Service and International Politics from the Pennsylvania State University and a Master's of Public Administration from Lehigh University. He is a recipient of the Order of Merit from the Federal Republic of Germany. In 2015, Moravian College conferred the honorary degree of Doctor of Laws upon Congressman Dent.

SUSAN DENTZER, Chair, Research!America; Senior Policy Fellow, Robert J. Margolis Center for Health Policy, Duke University

Susan Dentzer is Senior Policy Fellow at the Robert J. Margolis Center for Health Policy, the Washington, DC-based arm of Duke University that focuses on health system transformation, biopharmaceutical policy, and other key health policy issues, including multiple aspects of the COVID-19 pandemic. Dentzer is one of the nation's most respected health and health policy thought leaders and a frequent speaker and commentator on television and radio, including PBS and NPR, and an author of commentaries in *Modern Healthcare*, the *New England Journal of Medicine* and other prominent publications. She is also the editor and lead author of the book "Health Care Without Walls: A Roadmap for Reinventing U.S. Health Care."

Dentzer previously served as President and Chief Executive Officer of NEHI, the Network for Excellence in Health Innovation; senior policy adviser to the Robert Wood Johnson Foundation; editor-in-chief of the journal *Health Affairs*; and on-air Health Correspondent for the PBS NewsHour. She is an elected member of the National Academy of Medicine and the Council on Foreign Relations and is a fellow of the National Academy of

Social Insurance and the Hastings Center. She chairs the Board of Directors of Research!America, the nonprofit, nonpartisan organization that advocates for health-related research, and is a member of the Board of Directors of the International Rescue Committee, a leading global humanitarian organization. She also serves on the RAND Health Board of Advisors and is a fellow of the Hastings Institute and the National Academy of Social Insurance. Dentzer graduated from Dartmouth, is a trustee emerita of the college, and chaired the Dartmouth Board of Trustees from 2001 to 2004. Dentzer holds an honorary master's degree from Dartmouth and an honorary doctorate in humane letters from Muskingum University. She and her husband, Charles Alston, have three adult children.

LISA DESJARDINS, Correspondent, PBS NewsHour

Lisa Desjardins is a correspondent for PBS NewsHour, where she covers news from the U.S. Capitol while also traveling across the country to report on how decisions in Washington affect people where they live and work.

She specializes in breaking down complex stories and political disagreements into the key pieces that matter, often translating numbers and fiscal information into accessible stories for the audience.

Prior to joining NewsHour, Desjardins spent nearly ten years with CNN as a senior correspondent and Capitol Hill reporter. Prior to CNN, she reported for the Associated Press, WBTW-TV, WIS-TV, WTS-TV, Reuters, and The Sun News. At WIS in Columbia, South Carolina, she broke news of the compromise to bring down the Confederate flag from the state house dome.

Desjardins earned a bachelor's degree at the College of William and Mary and a master's degree from Northwestern University's Medill School of Journalism. She also received a first level graduate degree in Russian Studies from the Herzen State Pedagogical University of Russia.

Desjardins is the recipient of a Peabody Award for CNN's coverage of the 2008 election and a Society of Professional Journalists' Sigma Delta Chi award for national breaking news for coverage of the Haiti earthquake.

MIKAEL DOLSTEN, MD, PhD, Chief Scientific Officer and President, Worldwide Research, Development and Medical, Pfizer Inc

Mikael Dolsten focuses on advancing Pfizer's scientific breakthrough leadership in small-molecule medicines, biotherapeutics, gene therapies and vaccines. He is a member of the Executive Leadership Team and the company's Portfolio Strategy and Investment Committee, which governs major pipeline investments and strategic end-to-end R&D priorities.

Mikael leads the Worldwide Research, Development and Medical (WRDM) organization at Pfizer, which is responsible for the development of all compounds through proof of concept, and provides pharmaceutical sciences, safety and medical support to the entire R&D pipeline and all marketed medicines and vaccines. WRDM comprises all Pfizer research units, including Oncology, Internal Medicine, Inflammation & Immunology, Vaccines and Rare Disease, as well as the Centers for Therapeutic Innovation. The Vaccines R&D team leads

scientific efforts from discovery through registration of novel vaccines. Mikael also has worldwide responsibility for Pfizer's medical, safety and external R&D innovation, as well as science-based teams in pharmaceutical sciences, drug safety R&D, and large and small molecule discovery and development. Prior to joining Pfizer in 2009, Mikael was President of Wyeth Research, where he led scientists involved in all R&D/Medical activities across the US, Europe and Asia. Before that, Mikael served as Executive Vice President and Head of Worldwide Research for Boehringer Ingelheim from 2003-2008.

Mikael earned his PhD in tumor immunology and MD from the University of Lund in Sweden, where he was Adjunct Professor in Tumor Immunology and was recently appointed Visiting Professor to advise on science and technology strategies. He serves on the PhRMA Research & Development Leadership Forum as well as on the PhRMA Foundation Board of Directors. He is a member of the board of Karyopharm Therapeutics and of Research! America. Additionally, Mikael is a member of the Board of Overseers for the Scripps Research Institute and a Foreign Member of The Royal Swedish Academy of Engineering Sciences. Since 2014, Mikael has co-chaired the Accelerating Medicine Partnership with National Institutes of Health (NIH) Director Francis S. Collins. Mikael advised the Obama Administration on regulatory and drug development issues as well as then Vice President Biden's Cancer Moonshot Initiative to accelerate cancer research. Through 2019, Mikael was a council member of the Government-University-Industry Research Roundtable.

Mikael is a named inventor on several patents and has published approximately 150 articles in international journals, with contributions in molecular cell biology, immunology and oncology.

SHERRITA DORSEY, RN, MSN, FNP, Senior Director, Advocacy & Patient Engagement, Speciality Business Unit, GlaxoSmithKline

Sherrita is an accomplished and dynamic corporate healthcare executive with a nearly 22 year exemplary record of driving quality patient outcomes, revenue growth, and operational efficiencies in diverse roles, industries and specialties including Oncology, Rheumatology, Dermatology and Infectious Disease. She is currently serving as a Senior Director of Advocacy & Patient Engagement for GlaxoSmithKline in their Specialty Business Unit. Her previous experience includes leadership roles in regional and national sales, research, nursing and marketing at other globally recognized brands including AMGEN, Human Genome Science, Carmel Pharma & MD Anderson Cancer Center. Sherrita attributes her success to her diversified education, career experiences and global research experience which afforded her the privilege of being a published author before the age of 30. She is a recipient of the South African Minority International Research Traineeship (MIRT) funded by the National Institutes of Health (NIH). She contributes to her community through her membership with The Links, Inc. and Jack and Jill of America, Inc. among others. She is also the proud mother of two amazing children, Alexandria and Calvin Peete III.

KAFUI DZIRASA, MD, PhD, K. Ranga Rama Krishnan Endowed Associate Professor of Psychiatry & Behavioral Sciences, Duke University Medical Center

Kafui Dzirasa completed a PhD in Neurobiology at Duke University. His research interests focus on understanding how changes in the brain produce neurological and mental illness, and his graduate work has led to several distinctions including: the Somjen Award for Most Outstanding Dissertation Thesis, the Ruth K. Broad Biomedical Research Fellowship, the UNCF/Merck Graduate Science Research Fellowship, and the Wakeman Fellowship. Kafui obtained an MD from the Duke University School of Medicine in 2009, and he completed residency training in General Psychiatry in 2016.

Kafui received the Charles Johnson Leadership Award in 2007, and he was recognized as one of Ebony magazine's 30 Young Leaders of the Future in February 2008. He has also been awarded the International Mental Health Research Organization Rising Star Award, the Sydney Baer Prize for Schizophrenia Research, and his laboratory was featured on CBS 60 Minutes in 2011. In 2016, he was awarded the inaugural Duke Medical Alumni Emerging Leader Award and the Presidential Early Career Award for Scientists and Engineers: The Nation's highest award for scientists and engineers in the early stages of their independent research careers. In 2017, he was recognized as 40 under 40 in Health by the National Minority Quality Forum, and the Engineering Alumni of the Year from UMBC. He was inducted into the American Society for Clinical Investigation in 2019.

Kafui has served as an Associate Scientific Advisor for the journal Science Translational Medicine, a member of the Congressional-mandated Next Generation Research Initiative, the Editorial Advisory Board for TEDMED, and on the NIH Director's guiding committee for the BRAIN Initiative. He currently serves on the NIH Director's NExTRAC Advisory committee and Brain Initiative Multi-council working group.

Kafui is an Associate Professor at Duke University with appointments in the Departments of Psychiatry and Behavioral Sciences, Neurobiology, Biomedical Engineering, and Neurosurgery. His ultimate goal is to combine his research, medical training, and community experience to improve outcomes for diverse communities suffering from Neurological and Psychiatric illness.

GUNNAR ESIASON, Patient Advocate, Boomer Esiason Foundation

Gunnar Esiason is a cystic fibrosis and rare disease patient leader, who is passionate about early-stage drug development, patient empowerment and health policy. He has consulted with healthcare venture investors, assisted on clinical trial design, and has been the face of fundraising efforts for the Boomer Esiason Foundation, which has yielded more than \$160 million for the fight against cystic fibrosis. During the coronavirus pandemic, Gunnar was a leading voice for equitable vaccine access for people with underlying health conditions. His editorials have been published in USA Today, the Wall Street Journal, The Hill and STAT News. Gunnar holds an M.B.A. from the Tuck School of Business at Dartmouth.

ANTHONY S. FAUCI, MD, Director, National Institute of Allergy and Infectious Diseases, NIH

Dr. Fauci was appointed Director of NIAID in 1984. He oversees an extensive research portfolio of basic and applied research to prevent, diagnose, and treat established infectious diseases such as HIV/AIDS, respiratory infections, diarrheal diseases, tuberculosis and malaria as well as emerging diseases such as Ebola and Zika. NIAID also supports research on transplantation and immune-related illnesses, including autoimmune disorders, asthma and allergies. The NIAID budget for fiscal year 2021 is an estimated \$6.1 billion.

Dr. Fauci has advised seven Presidents on HIV/AIDS and many other domestic and global health issues. He was one of the principal architects of the President's Emergency Plan for AIDS Relief (PEPFAR), a program that has saved millions of lives throughout the developing world.

RACHEL FONES, Director, Government & Public Affairs, IQVIA

Rachael Fones serves as Director, Government & Public Affairs and co-lead of the Diversity in Clinical Trials Steering Committee for IQVIA, as well as Chair of the Association of CROs (ACRO) Diversity & Inclusion Committee. With 16 years at IQVIA and seven in her current role, Fones works with trade associations, advocacy groups and government officials to identify opportunities to advance the clinical research ecosystem.

Passionate about making progress on Diversity in Clinical Trials (DICT), Fones has been an active participant on a number of initiatives over the past several years, including with the Multi-Regional Clinical Trials Center of Brigham and Women's Hospital and Harvard University's (MRCT) Diversity in Clinical Trials workgroup since 2017, and served on the planning committee for the Society for Women's Health Research 2016 workshop, "Achieving Meaningful Subgroup Data in Clinical Trial Design and Development".

Fones leverages her background and insights from these efforts and practical experience, serving as a frequent speaker and a strategic advisor for IQVIA's Diversity in Clinical Trials initiatives and customer solutions, as well as with policymakers.

Prior to joining IQVIA (then Quintiles), Fones worked on health care policy and advocacy for Blue Cross and Blue Shield of Florida and as the Executive Director of the Health Care Quality Alliance in Washington, DC, a member organization bringing together patient, physician, industry and issue advocacy groups, including Research!America.

TOM FRIEDEN, MD, MPH, President and CEO, Resolve to Save Lives; Former Director, CDC

Dr. Tom Frieden is a physician trained in internal medicine, infectious diseases, public health, and epidemiology. He is former director of the U.S. Centers for Disease Control and Prevention and former commissioner of the New York City Health Department. Dr. Tom Frieden is currently President and CEO of Resolve to Save Lives, an initiative of the global health organization Vital Strategies.

Dr. Tom Frieden began his public health career in New York City identifying then leading the effort that stopped the largest outbreak of multi-drug resistant tuberculosis to occur in the U.S. He was then assigned to India, on loan from the Centers for Disease Control and Prevention, where he helped scale up a program for effective tuberculosis diagnosis, treatment, and monitoring. Asked to return to New York City to become Mayor Mike Bloomberg's Health Commissioner, he directed efforts to reduce smoking and other leading causes of death

that increased life expectancy by 3 years. As Director of the U.S. Centers for Disease Control and Prevention, Dr. Frieden oversaw the work that helped end the 2014 West Africa Ebola epidemic. He now leads Resolve to Save Lives, an initiative of the global health organization Vital Strategies, that partners with countries to prevent 100 million deaths and to make the world safer from epidemics. During the Covid pandemic, Dr. Frieden has overseen an expansion of Resolve to Save Lives activities including policy and program innovations in the United States, counsel and support to multilateral institutions, and support for rapid response, health care worker safety, and data-driven decision-making in more than 20 countries. Dr. Tom Frieden is also Senior Fellow for Global Health at the Council on Foreign Relations.

SANTIAGO GONZALEZ, MPH, Senior Policy Advisor, Senator Michael Bennet (D-CO)

Santiago Gonzalez is the Senior Policy Advisor for Senator Michael Bennet (D-CO), a member of the Senate Finance Committee. He advises the Senator on health and immigration policy, including Medicare, Medicaid, FDA, public health, and disparities. Previously he worked as Policy Advisor to Representative Jason Crow (D-CO) and Legislative Aide to Senator Heidi Heitkamp (D-ND). Prior to working in Congress, Santiago was a Health Policy Research Associate at FBR Capital Markets and Research Assistant at the George Washington University's Milken Institute School of Public Health. He received his MPH, focusing on Health Policy, from the George Washington University and has a BA in Biochemistry and Chemistry from the University of Colorado - Boulder.

THE HONORABLE JOSH GOTTHEIMER, U.S. Representative (D-NJ-05)

Josh Gottheimer represents New Jersey's Fifth Congressional District in the northern part of the state, which includes parts of Bergen, Passaic, Sussex, and Warren counties. In Congress, Gottheimer serves on two Committees, including the House Financial Services Committee, where he is the Vice Chair of the National Security, International Development and Monetary Policy Subcommittee and a member of the Investor Protection, Entrepreneurship and Capital Markets Subcommittee. Gottheimer also serves on the House Homeland Security Committee, where he is a member of the Intelligence and Counterterrorism Subcommittee and the Transportation and Maritime Security Subcommittee. Gottheimer serves as Co-Chair of the bipartisan Problem Solvers Caucus, where he works across party lines to find areas of agreement on key issues including cutting taxes and outdated regulation, lowering health insurance costs, and improving infrastructure.

SCOTT GOTTLIEB, MD, Former FDA Commissioner; Fellow, American Enterprise Institute; Author, *Uncontrolled Spread*

Dr. Scott Gottlieb served as the twenty-third commissioner of the US Food and Drug Administration and is a resident fellow at the American Enterprise Institute. His first book, "Uncontrolled Spread: Why COVID-19 Crushed Us and How We Can Defeat the Next Pandemic," was published in September 2021. He is also a regular contributor to the business news channel CNBC and a partner at the venture capital firm New Enterprise Associates.

Dr. Gottlieb serves on the board of directors of the pharmaceutical company Pfizer, Inc. and the genomic sequencing company Illumina, Inc. Fortune magazine has recognized him as one of the “World’s 50 Greatest Leaders,” and Time magazine has named him one of its “50 People Transforming Healthcare.” A graduate of Wesleyan University and the Mount Sinai School of Medicine, Dr. Gottlieb is an elected member of the National Academy of Medicine. He lives with his family in Westport, Connecticut.

WILLIAM N. HAIT, MD, PhD, Global Head, Johnson & Johnson Global External Innovation

Dr. William N. Hait leads the external sourcing and creation of transformational innovation to help Johnson & Johnson achieve its mission to change the trajectory of health for humanity. He works on building an enterprise-wide external R&D pipeline, creating innovative solutions that utilize J&J’s excellence in pharmaceuticals, medical devices and consumer products. His team strives to identify disruptive technologies and cutting-edge early innovations in disease areas of emphasis at J&J, to eliminate disease through prevention, interception and cures.

Dr. Hait joined J&J in 2007 and served as Global Therapeutic Area Head for Oncology from 2009 to 2011, and then as Global Head, Janssen Research & Development, from 2011 through 2018. Before that, he was the founding Director of The (Rutgers) Cancer Institute of New Jersey. From 1993 to 2007, he was Professor of Medicine and Pharmacology and Associate Dean for Oncology Programs at the University of Medicine and Dentistry of New Jersey – Robert Wood Johnson Medical School.

Dr. Hait joined the Yale University School of Medicine faculty in 1984 and became Associate Professor of Medicine and Pharmacology, Chief of the Division of Medical Oncology, Associate Director of the Yale University Comprehensive Cancer Center, Director of the Breast Cancer Unit and Co-Director of the Lung Cancer Unit. He is Board Certified in Internal Medicine and Medical Oncology.

He devoted time to numerous advisory and editorial boards, served in a range of scientific functions, societies and committees, was elected President of the American Association for Cancer Research (2007 – 2008) and has received numerous awards and honors.

CHRISTINA HARTMAN, Vice President of External Affairs, The Assistance Fund

As Vice President of External Affairs, Christina leads the Assistance Fund’s (TAF) Washington, DC, office and its efforts to pave the way for patient-focused policy and advocacy to lower patients’ out-of-pocket costs and ensure their access to critical treatment.

Christina came to TAF from the EveryLife Foundation, where she led policy and advocacy efforts to advance treatment and diagnostic opportunities for rare disease patients. At the American College of Cardiology, she worked with staff and member leadership to improve cardiovascular health outcomes. At the Pew Charitable Trusts, Christina worked with a range of partners to advance legislative goals that incentivize the development of new antibiotic drugs. As an analyst at the Centers for Disease Control and Prevention and in the Office of the Secretary for the U.S. Department of Health and Human Services, (HHS), she served as Project Officer for a

cooperative agreement between HHS and the World Health Organization. Christina's engagement in the rare disease space is a direct result of her own experience with her youngest daughter Charlotte, who has a rare genetic disorder. She has a bachelor's degree from The Catholic University of America and a Master of Public Health from The George Washington University.

LAURIE HERNANDEZ, Olympic Gymnastics Champion and One Mind Ambassador

Since bringing home the Gold and Silver medals at the 2016 Rio Olympic Games, Laurie has gone on to win the coveted Mirror ball trophy on "Dancing with the Stars" Season 23 and wrote her first book titled "I Got This: To Gold and Beyond" published in 2017, hitting the New York Times Best Sellers list. In 2018, she released a children's picture book "She's Got This" with HarperCollins Children's Books, also a NYT Best Seller, while serving as a Literacy Champion to promote readership as a path to leadership. Mattel created a Laurie Hernandez "Shero" Barbie to honor her.

She is a second generation American, as her grandparents are from Puerto Rico, making her the first U.S.-born Latina to make the U.S. team since 1984. Laurie is currently the Gymnastics analyst for Peacock and the Olympic Channel for the Tokyo 2020 Olympic Games. When not in the gym, Laurie enjoys spending time with her family. Acting is one of her biggest passions and she has done cameos, voiceovers, and co-hosted American Ninja Warrior Junior, and plans to pursue an acting/screenwriting degree. She travels the country speaking to the next generation about following your dreams. She is also a fierce advocate for the importance of Mental Health and has partnered with multiple campaigns and initiatives to encourage awareness.

STACY HOLDSWORTH, PharmD, Senior Advisor, U.S. Regulatory Policy and Strategy, Eli Lilly and Company

Stacy Holdsworth is the Senior Advisor for U.S. Regulatory Policy & Strategy at Eli Lilly and Company. Her primary responsibilities are to lead a team of regulatory professionals in the development and implementation of a regulatory policy agenda that encourages innovation and delivers a pipeline of new medicines for patients. Stacy has been in her current role for more than ten years and has supported regulatory policy initiatives ranging from influencing the use of benefit/risk assessment in regulatory decision making, to shaping pediatric study requirements, to encouraging the use of real world evidence in pre and post approval regulatory decisions. During her career, Stacy has been involved in multiple PDUFA negotiations and other discussions about FDA-related legislation.

In her prior roles at Lilly, Stacy led the regulatory advertising and promotion group, during which she was responsible for oversight of efforts to optimize communications and education about medicines to health care professionals and patients while ensuring compliance with relevant laws and regulations. She has also worked in regulatory intelligence collecting and interpreting regulatory precedence and new developments in order to inform regulatory strategies during drug development. To start her career, Stacy completed the Lilly Visiting Scientist Fellowship Program in regulatory affairs focused on late-stage endocrine product development. She received her Doctor of Pharmacy degree from Butler University.

KAYE HUSBANDS FEALING, PhD, Dean, Ivan Allen College of Liberal Arts, Georgia Institute of Technology

Kaye Husbands Fealing is Dean of the Ivan Allen College of Liberal Arts at the Georgia Institute of Technology, formerly the Chair of the School of Public Policy, Georgia Tech. She specializes in science of science and innovation policy, the public value of research expenditures, and the underrepresentation of women and minorities in STEM fields and workforce. Prior to her position at Georgia Tech, Husbands Fealing taught at the Humphrey School of Public Affairs, University of Minnesota, and she was a study director at the National Academy of Sciences. Prior to the Humphrey School, she was the William Brough professor of economics at Williams College, where she began her teaching career in 1989. She developed and was the inaugural program director for the National Science Foundation's (NSF) Science of Science and Innovation Policy program and co-chaired the Science of Science Policy Interagency Task Group, chartered by the Social, Behavioral and Economic Sciences Subcommittee of the National Science and Technology Policy Council. At NSF, she also served as an Economics Program director. Husbands Fealing was a visiting scholar at Massachusetts Institute of Technology's Center for Technology Policy and Industrial Development, where she conducted research on NAFTA's impact on the Mexican and Canadian automotive industries, and research on strategic alliances between aircraft contractors and their subcontractors.

Husbands Fealing became an Elected Member of the American Academy of Arts and Sciences in 2021. She also is an Elected Fellow of the National Academy of Public Administration, an Elected Fellow of the American Association for the Advancement of Science (AAAS), and serves on the AAAS Executive Board. She was awarded the 2017 Trailblazer Award from the National Medical Association Council on Concerns of Women Physicians. She currently serves on NSF's Committee on Equal Opportunities in Science and Engineering, NSF's Education and Human Resources Directorate's Advisory Committee, the General Accountability Office's Science, Technology Assessment, and Analytics Polaris Council, and the Georgia Intellectual Property Alliance. She is a board member for the Society for Economic Measurement. She has served on several committees and panels, including: several AAAS committees; three National Academies' panels; two Council of Canadian Academies panels; two American Academy of Arts and Sciences working groups; NSF's Social, Behavioral, and Economic Sciences Advisory Committee; NIH's National Institute of General Medical Sciences Council; and the American Economic Association's Committee on the Status of Women in the Economic Profession. At Georgia Tech, she serves on the Institute for Data Engineering and Science Council, the Intellectual Property Advisory Board, and the Ivan Allen College Diversity Council.

Husbands Fealing holds a PhD in economics from Harvard University, and a BA in mathematics and economics from the University of Pennsylvania.

HALLIE JACKSON, Senior Washington Correspondent, NBC News; Host, MSNBC'S "Hallie Jackson Reports"

Hallie Jackson is the senior Washington correspondent for NBC News, covering the biggest stories from our nation's capital, and hosts the 10 a.m. hour of "MSNBC Reports." Jackson is a fill-in anchor for "NBC Nightly News" and "TODAY" and her reporting appears across all NBC News and MSNBC platforms and NBCNews.com.

In February 2020, Jackson co-moderated the NBC News and MSNBC Democratic presidential debate in Las Vegas, Nevada, the most watched Democratic presidential debate in history with nearly 20 million viewers.

Previously, Jackson was NBC News' Chief White House Correspondent covering President Donald Trump's administration, from the inauguration through the impeachment trial and the 2020 election. Jackson traveled with the president for every key international trip, including the summits with Kim Jong Un and the anniversary of D-Day in Normandy. In 2017, Jackson became the host of the 10 a.m. hour on MSNBC where she brings well-sourced updates and breaks down key developments from Washington. While reporting on the 2016 campaign trail, Jackson consistently broke developments in the election cycle and scored exclusive interviews with several GOP candidates including Donald Trump, Sen. Ted Cruz, Sen. Marco Rubio and Ben Carson.

Before covering politics for the network, Jackson reported from NBC News' Los Angeles bureau for a year. Prior to joining the network in 2014, Jackson was a national correspondent for Hearst Television in Washington, D.C., providing daily coverage of political and national events for its 26 affiliates across the country. She has also worked for WFSB-TV in Hartford, Conn. and was a general assignment reporter for WBOC-TV in Salisbury, Maryland. Jackson, a native of Yardley, Pa., graduated from The Johns Hopkins University with a bachelor's degree in political science.

AMANDA JEZEK, Senior Vice President, Public Policy and Government Relations, Infectious Diseases Society of America

Amanda Jezek is the Senior Vice President of Public Policy and Government Relations at the Infectious Diseases Society of America. She leads policy development and advocacy with a focus on pandemic preparedness & response, antimicrobial resistance and incentives for antibiotic and diagnostic R&D, and efforts to strengthen the infectious diseases workforce. Previously, Ms. Jezek worked as the Deputy Director of Federal Affairs for March of Dimes. She holds a degree in Political Science and Government from Dartmouth College.

EMIL KAKKIS, MD, PhD, CEO, President and Founder, Ultragenyx Pharmaceutical Inc.

Dr. Kakkis is Chief Executive Officer, President and Founder of Ultragenyx Pharmaceutical where he leads a team developing and commercializing multiple rare and ultra-rare disease treatments. Over the last 25 years, Dr. Kakkis is best known for his work developing novel treatments for rare diseases and for advocating on policy issues by founding and supporting the EveryLife Foundation for Rare Diseases. He began his work as an assistant professor developing an enzyme replacement therapy (Aldurazyme®) for the rare disorder MPS I. After joining BioMarin in 1998, Dr. Kakkis guided the development and approval of two more treatments for rare diseases and has contributed to the development of approved or development stage products of four other treatments for rare diseases. Dr. Kakkis went on to found Ultragenyx in 2010 to focus on developing as many rare and ultra-rare disease therapeutics. Since its founding, Ultragenyx has worked on developing treatments for twenty different genetic diseases and has now received commercial approvals for its first three products to treat four diseases. Through his career, he has contributed to the approvals of treatments for MPS I, MPS VI, MPS IVa and MPS VII. Dr. Kakkis graduated from Pomona College, magna cum laude and received combined MD

and PhD degrees from the UCLA Medical Scientist Program. He completed both a Pediatrics residency and Medical Genetics Training Fellowship at Harbor- UCLA Medical Center. Dr. Kakkis received the Lifetime Achievement Award from the National MPS Society and the Henri Termeer Visionary Leader Award from BIO in 2019.

MIA R. KEEYS, MA, Chief of Staff, Congresswoman Robin L. Kelly (IL-02)

Mia R. Keays is the Chief of Staff for Congresswoman Robin L. Kelly (IL-02). She previously was the Director of Health Equity Policy & Advocacy with the American Medical Association. She formerly served as the Policy Director of Congresswoman Robin Kelly's (D-IL) Congressional Black Caucus (CBC) Health Braintrust, the premier health policy arm of the CBC.

In April 2017, The National Minority Quality Forum recognized Mia as a 40 Under 40 Leader in Minority Health. The Institute of Medicine of the National Academy of Sciences features Mia's children's book on health equity—titled *Cole Blue, Full of Valor*—in their national archives, "Visualizing Health Equity." Mia has been a Kaiser Family Foundation Barbara Jordan Health Policy Scholar; a Fellow for the City of Philadelphia in the Deputy Mayor's Office for Health and Opportunity; and an HIV/AIDS researcher in South Africa. Mia was also a U.S. Fulbright Fellow to Indonesia, where she lived and worked in various teaching, public health service and research capacities for three years, while simultaneously learning the national language, Bahasa Indonesian.

Mia holds Bachelor of Arts degrees in English and Psychology from Cheyney University, and a Master of Arts degree in Medical Sociology from Vanderbilt University in Nashville, TN, where she was also a Robert Wood Johnson Foundation Health Policy Fellow at Meharry Medical College. She is currently a doctoral of public health student at The George Washington University. Mia is also a creative non-fiction writer, with training from the University of Oxford. She is originally from Philadelphia, PA.

THE HONORABLE PATRICK J. KENNEDY, Former U.S. Representative (D-RI); Founder, The Kennedy Forum

During his time in Congress, Patrick J. Kennedy was the lead author of the landmark Mental Health Parity and Addiction Equity Act (Federal Parity Law), which requires insurers to cover treatment for mental health and substance use disorders no more restrictively than treatment for illnesses of the body, such as diabetes and cancer. In 2013, he founded The Kennedy Forum, a nonprofit that unites advocates, business leaders, and government agencies to advance evidence-based practices, policies, and programming in mental health and addiction. In 2015, Kennedy co-authored the New York Times Bestseller, "A Common Struggle: A Personal Journey Through the Past and Future of Mental Illness and Addiction," which details a bold plan for the future of mental health care in America. In 2017, he was appointed to the President's Commission on Combating Drug Addiction and the Opioid Crisis.

Kennedy is also the founder of DontDenyMe.org, an educational campaign that empowers consumers and providers to understand parity rights and connects them to essential appeals guidance and resources; co-founder of One Mind, an organization that pushes for greater global investment in brain research; and

co-chair of the Mental Health & Suicide Prevention National Response to COVID-19, an initiative of the National Action Alliance for Suicide Prevention.

IAN KREMER, JD, Executive Director, Leaders Engaged on Alzheimer’s Disease (LEAD) Coalition

Ian N. Kremer, JD, has worked on federal, state and local dementia policy since 1996. Since 2012, Kremer has served as Executive Director of the LEAD Coalition (Leaders Engaged on Alzheimer’s Disease), the uniting voice of over 200 member and allied organizations. The LEAD Coalition accelerates transformational progress in care and support to enrich the quality of life of those with dementia and their caregivers, detection and diagnosis, and research leading to prevention, effective treatment, and cures. The LEAD Coalition has helped to secure historic funding increases for the National Institutes of Health (NIH), expand Medicare services for people with dementia and protect dementia-relevant components of Medicaid and the Patient Protection and Affordable Care Act, expand the role of people with dementia and their care partners in medical product development, build a nation-wide network of dementia-friendly communities, and worked with a dozen federal agencies to overcome health disparities, clarify regulatory pathways, combat elder abuse, and improve cognitive impairment detection and diagnosis, clinical care, and access to home and community-based services.

Kremer serves on the steering committee for NIH 2020 National Research Summit on Care, Services, and Supports for Persons with Dementia and Their Caregivers and served on the 2017 Summit steering committee. He also serves on the Public Policy & Aging Report editorial board, and on steering and advisory committees for the National Institute on Aging (NIA), IMbedded Pragmatic AD/ADRD Clinical Trials (IMPACT) Collaboratory, the CDC-funded NYU School of Medicine BOLD Public Health Center of Excellence on Early Detection of Dementia, the CDC National Healthy Brain Initiative Tribal Project, the NIA-funded Hopkins’ Economics of Alzheimer’s Disease and Services (HEADS) Center, the UCLA Dementia Care Study, the Alzheimer’s Disease Patient and Caregiver Engagement (AD PACE) initiative, the Dementia Friendly America initiative, the Brain Health Partnership, the Alzheimer’s Disease Partnership for Evidence and Value (AD EVAL) and Dementia Alliance International. Kremer was an external reviewer for the 2021 National Academies of Science, Engineering, and Medicine report, “Meeting the Challenge of Caring for Persons Living with Dementia and Their Care Partners and Caregivers: A Way Forward.” Previously, Kremer has served on steering and advisory committees for a wide variety of organizations including the CDC Healthy Brain Initiative Roadmap, the Gerontological Society of America Workgroup on Cognitive Impairment Detection and Earlier Diagnosis, and the PCORI Dementia Research Methods project. Kremer holds degrees from Washington University in Saint Louis and the University of Michigan School of Law.

LISA LACASSE, President, American Cancer Society Cancer Action Network

Lisa Lacasse is the president of the American Cancer Society Cancer Action Network (ACS CAN), the nonprofit, nonpartisan advocacy affiliate of the American Cancer Society (ACS). She leads an organization of staff in Washington, DC and across the country in support of laws and policies that help people fight cancer and advance the ACS’ mission.

Since joining ACS CAN in 2007, Lisa has been integrally involved in helping to establish a nationwide public health advocacy organization that influences and shapes public policy at all levels of government. Her passion for representing the voices of all cancer patients and their families is exemplified in her leadership.

In her former capacity as deputy president, Lisa managed a broad portfolio in support of ACS CAN's advocacy priorities. The focus of her work was on strategic integration and organizational alignment across the enterprise. Her responsibilities included organizational development and training, volunteer engagement and grassroots strategy, media advocacy, public policy, finance, governance, human resources, and all ACS CAN operations.

Lisa received a Master of Business Administration degree from the Wharton School at the University of Pennsylvania and a Bachelor of Arts degree from the University of Vermont. Before joining ACS CAN, she was the chief financial officer at the National Institutes of Health (NIH) Clinical Research Center, a 242-bed, clinical research hospital where she was responsible for the planning, formulation, and execution of a \$345 million annual budget. Prior to NIH, Lisa spent several years in senior management at the University of Maryland Medical System and began her career in the office of the Governor of the State of Maine. Lisa lives in Bethesda, Maryland. She loves nothing more than spending time with her husband and four children in her beloved home state of Maine.

ERIC LANDER, PhD, Director, Office of Science and Technology Policy; Science Advisor to the President

Dr. Eric S. Lander is the President's Science Advisor and Director of the White House Office of Science and Technology Policy (OSTP). A member of the Cabinet, Lander was sworn in on June 2, 2021 after being unanimously confirmed by the Senate. He leads OSTP in its mission to maximize the benefits of science and technology to advance health, prosperity, security, environmental quality, and justice for all Americans.

Lander was formerly president and founding director of the Broad Institute, a deeply collaborative research institute – closely affiliated with the Massachusetts Institute of Technology, Harvard University, and five of Boston's major hospitals – that propels work on genomic medicine. A geneticist, molecular biologist, and mathematician, Lander has played a pioneering role in all aspects of the reading, understanding, and biomedical application of the human genome, and has been a consistent champion of making gene sequencing data rapidly and openly available. He was one of the principal leaders of the international Human Genome Project (HGP) from 1990 to 2003, with his center being the largest contributor to the mapping and sequencing of the human blueprint.

Lander is professor of biology at MIT and professor of systems biology at Harvard Medical School; he is currently on leave from both institutions. He has served on governing and advisory boards for various government agencies, academic institutions, and scientific societies, and has co-founded several successful biotechnology firms.

From 2009 to 2017, Lander served as external co-chair of the President's Council of Advisors on Science and Technology (PCAST), advising the White House for all eight years of the Obama-Biden administration. PCAST is a council of the nation's leading scientists and engineers, which advises the White House on matters including health, advanced manufacturing, energy policy, information technology, drug innovation, spectrum and communications policy, nanotechnology, and national security. He also served on the Defense Department's Defense Innovation Board from 2016 to 2020.

In 1990, he founded the Whitehead/MIT Center for Human Genome Research, which became a flagship and leading contributor to the Human Genome Project. As the Human Genome Project reached its successful conclusion, Lander sought to perpetuate the interdisciplinary and interinstitutional collaborative spirit of the center by creating a permanent institution.

In 2004, Lander founded the Broad Institute of Harvard and MIT, a unique research institution focused on genomic medicine that spans Harvard University, Massachusetts Institute of Technology, and the Harvard-affiliated hospitals. Now involving a community of more than 3000 people, the Broad has become a model for a new kind of collaborative biomedical research community, enabling creative scientists to tackle important challenges that span medicine, biology, chemistry, mathematics, computer science, and engineering.

Lander's honors and awards include the MacArthur Fellowship, the Breakthrough Prize in Life Sciences, the Albany Prize in Medicine and Biological Research, the Gairdner Foundation International Award of Canada, the Dan David Prize of Israel, the Mendel Medal of the Genetics Society in the UK, the City of Medicine Award, the Abelson Prize from the AAAS, the Award for Public Understanding of Science and Technology from the AAAS, the Woodrow Wilson Prize for Public Service from Princeton University, the James R. Killian Jr. Faculty Achievement Award from MIT, and the William Allan Award from the American Society of Human Genetics. He was elected a member of the U.S. National Academy of Sciences in 1997 and of the U.S. Institute of Medicine in 1999. In 2013, he was elected to the Royal Swedish Academy of Sciences and in 2020, he was appointed to the Pontifical Academy of Sciences. He has received honorary degrees from 12 colleges and universities.

Lander earned his BA in mathematics from Princeton University (1978) and his PhD in mathematics from Oxford University (1981) as a Rhodes Scholar. He and his wife Lori are the proud parents of three adult children, Jessica, Daniel, and David, and one golden retriever.

THOMAS LaVEIST, PhD, Dean and Weatherhead Presidential Chair in Health Equity, Tulane University School of Public Health and Tropical Medicine

Thomas LaVeist is dean of the Tulane University, School of Public Health and Tropical Medicine. He has written over 150 scientific articles, numerous mass media outlets, authored six books, and is executive producer of "The Skin You're In" documentary series about racial inequalities in health. An award winning research scientist, Dr. LaVeist has received the "Innovation Award" from National Institutes of Health, the "Knowledge

Award” from the U.S. Department of Health and Human Services and was elected to the National Academy of Medicine.

RITA LIVADAS, PharmD, Director of Public Affairs, BD

Rita Livadas earned her PharmD from Rutgers University and her MPH from the University of Pittsburgh. She is the Director of Public Affairs for BD. She previously worked in the office of Senator Michael Bennet (D-CO) as the Senior Policy Advisor, where she worked on Senate Biomedical Innovation Package legislation as well as on priorities for the Senate Finance Committee Bipartisan Chronic Care Working Group.

JENNY LURAY, Vice President of Strategy and Communications, Research!America

Jenny Luray is Vice President of Strategy and Communications. Jenny served as Chief of Staff to former Senator Barbara Mikulski, Legislative Director to Congresswoman Nita Lowey and Deputy Assistant to the President in the Clinton White House. She directed U.S. policy and government affairs for BD and Abbott as well as led the Susan G. Komen Advocacy Alliance as its president. Jenny sits on the Governing Committee of the FDA-supported NESTcc, and on the Advisory Council of the Brown University School of Public Health.

JOHN MARAGANORE, PhD, CEO, Alnylam

Dr. John Maraganore serves as the CEO and a Director of Alnylam, the company that translated Nobel prize-winning RNA interference (RNAi) into a whole new class of innovative medicines. You don't need to look further than Dr. Maraganore's Twitter handle (@jmaraganore) to see that he is a passionate advocate for the biotech industry and a believer in pushing the boundaries of medicine to help patients. Dr. Maraganore supports the industry at large, serving on the boards of directors for growing biotech companies like Agios Pharmaceuticals. He is a longtime member and former chair of the Biotechnology Industry Organization (BIO) Board and member of the BIO Executive Committee.

A 30-year industry veteran, Dr. Maraganore is a sought after speaker at national healthcare forums such as the Forbes Healthcare Summit, Financial Times' Biotech and Pharmaceutical Global Conference, J.P. Morgan, Prix Galien USA, World Orphan Drug Congress and FDA/CMS Summit, and is also a trusted industry expert for top media outlets including The Wall Street Journal, New York Times, Forbes, Bloomberg, The Boston Globe and CNBC. Dr. Maraganore has also received major industry kudos - listed in the Bloomberg 50 Who Defined Global Business in 2018, voted Best Biopharma CEO of 2017 and 2019 by STAT News, won the CEO award from Xconomy's Best of Boston Life Science in 2018, honored with MassBio's Innovative Leadership Award in 2016 and honored by PharmaVOICE 100 in 2009.

Before joining Alnylam, Dr. Maraganore served as an officer, member of the management team, and Senior Vice President, Strategic Product Development for Millennium Pharmaceuticals, Inc. He oversaw the company's franchises in oncology, and cardiovascular, inflammatory and metabolic diseases.

Prior to Millennium, Dr. Maraganore served as Director of Molecular Biology and Director of Market and Business Development at Biogen, Inc., where he invented and led the discovery and development of Angiomax™ (bivalirudin for injection, formerly Hirulog™) currently marketed by The Medicines Company. Dr. Maraganore received his MS and PhD in biochemistry and molecular biology at the University of Chicago.

PETER MARKS, MD, PhD, Director, Center for Biologics Evaluation & Research, FDA

Peter Marks, MD, PhD is the director of the Center for Biologics Evaluation and Research (CBER) at the Food and Drug Administration. The center is responsible for assuring the safety and effectiveness of biological products, including vaccines, allergenic products, blood and blood products, and cellular, tissue, and gene therapies. Dr. Marks and center staff are committed to facilitating the development of biological products and providing oversight throughout the product life cycle.

Dr. Peter Marks received his graduate degree in cell and molecular biology and his medical degree at New York University. Following this, he completed an Internal Medicine residency and Hematology/Medical Oncology fellowship at Brigham and Women's Hospital in Boston, where he subsequently joined the attending staff as a clinician-scientist and eventually served as Clinical Director of Hematology.

He then moved on to work for several years in the pharmaceutical industry on the clinical development of hematology and oncology products prior to returning to academic medicine at Yale University where he led the Adult Leukemia Service and served as Chief Clinical Officer of Smilow Cancer Hospital. He joined the FDA in 2012 as Deputy Center Director for CBER and became Center Director in 2016. Dr. Marks is board certified in internal medicine, hematology and medical oncology, and is a Fellow of the American College of Physicians.

MARK McCLELLAN, MD, PhD, Director, Robert J. Margolis Center for Health Policy, Duke University; Former Administrator, CMS, 2004-2006; Former Commissioner, FDA, 2002-2004

Mark McClellan, MD, PhD, is Director and Robert J. Margolis, M.D., Professor of Business, Medicine and Policy at the Margolis Center for Health Policy at Duke University. He is a physician-economist who focuses on quality and value in health care, including payment reform, real-world evidence and more effective drug and device innovation. Dr. McClellan is at the center of the nation's efforts to combat the pandemic and the author of a roadmap that details the steps needed for a comprehensive COVID-19 response and safe reopening of our country. He is former administrator of the Centers for Medicare & Medicaid Services and former commissioner of the U.S. Food and Drug Administration, where he developed and implemented major reforms in health policy. Dr. McClellan is an independent director on the boards of Johnson & Johnson, Cigna, Alignment Healthcare, and PrognomiQ; co-chairs the Guiding Committee for the Health Care Payment Learning and Action Network; and serves as an advisor for Arsenal Capital Group, Blackstone Life Sciences, and MITRE.

DONNA McKELVEY, Vice President of Alliance Development and Membership, Research!America

Donna McKelvey is Vice President of Alliance Development and Membership of Research!America. Previously, she served as the Chief Development Officer for Food Allergy Research and Education, overseeing the revenue and relationship development for major gifts, individual giving, membership, corporate and foundation and special events on a national level. She has also spent more than 20 years of her career as a leader, both on a local level and the national level, with The Leukemia & Lymphoma Society, including serving as the Executive Director for the Organization's National Capital Area Chapter and the Rhode Island Chapter, as well as serving as a National Field Director. Prior to her experience in non-profit, Donna was the Director of Sales and Marketing for boutique hotels in the hospitality industry.

MARCIA McNUTT, PhD, President, National Academy of Sciences

Marcia McNutt (BA in physics, Colorado College; PhD in Earth sciences, Scripps Institution of Oceanography) is a geophysicist and the 22nd president of the National Academy of Sciences. From 2013 to 2016, she was editor-in-chief of Science journals. McNutt was director of the U.S. Geological Survey from 2009 to 2013, during which time USGS responded to a number of major disasters, including the Deepwater Horizon oil spill. For her work to help contain that spill, McNutt was awarded the U.S. Coast Guard's Meritorious Service Medal. She is a fellow of the American Geophysical Union, Geological Society of America, the American Association for the Advancement of Science, and the International Association of Geodesy. McNutt is a member of the National Academy of Engineering, the American Philosophical Society and the American Academy of Arts and Sciences, and a Foreign Member of the Royal Society, UK, the Russian Academy of Sciences, and the Chinese Academy of Sciences. In 1998, McNutt was awarded the AGU's Macelwane Medal for research accomplishments by a young scientist, and she received the Maurice Ewing Medal in 2007 for her contributions to deep-sea exploration.

DAVID MEYERS, PhDMD, Acting Director, Agency for Healthcare Research and Quality

Dr. Meyers, a board-certified family physician, began serving as AHRQ's Acting Director on January 12, 2021. He leads the Agency's mission of producing evidence to make health care safer, higher quality, more accessible, equitable, and affordable, and working within the U.S. Department of Health and Human Services and with other Federal, State, and local partners to make sure that the evidence is understood and used.

Dr. Meyers joined AHRQ in 2004 and has served under four previous AHRQ directors. Since February 2020 he has been the Agency's Deputy Director where he led many of AHRQ's strategic planning activities and co-led the development of AHRQ's National Nursing Home COVID-19 Action Network.

Prior to his appointment as Deputy Director, he served as AHRQ's first chief physician and directed EvidenceNOW, AHRQ's \$110 million initiative to help primary care practices improve the heart health of their patients through quality improvement support and the implementation of new evidence. During his more than 15 years with AHRQ, Dr. Meyers has directed the Agency's Center for Primary Care, Prevention and Clinical Partnerships and established its Center for Evidence and Practice Improvement. He has also directed the Agency's Practice-Based Research Network initiatives and served as the Acting Scientific Director for the U.S. Preventive Services Task Force. Dr. Meyers' recent publications focus on the primary care workforce,

supporting quality improvement in primary care practice, utilization of clinical preventive services, and trust in the physician-patient relationship.

Before joining AHRQ in 2004, he practiced family medicine, including maternity care, in a community health center in southeast Washington, D.C., and directed the Georgetown University Department of Family Medicine's practice-based research network, CAPRICORN. He is a graduate of the University of Pennsylvania School of Medicine and completed his family medicine residency at Providence Hospital/Georgetown University. After residency, he completed fellowship training in primary care health policy and research in the Department of Family Medicine at Georgetown University. In 2019, he was elected a member of the National Academy of Medicine.

KEILA MILES, PhD, Community Features Coordinator, VanGuard STEM

Dr. Keila Miles is the first Black woman to earn a PhD in Neuroscience from the University of Cincinnati, College of Medicine. Her dissertation research focused on the use of a ketogenic diet as a potential treatment for Creatine Transporter Deficiency, a rare metabolic disorder that causes intellectual disability. During her tenure as a doctoral candidate, she wrote a successfully funded NIH grant application (F-31 Diversity), installed a diversity and inclusion organization for shaping STEM leaders (Cincy-Society for Advancing Chicanos, Hispanics, and Native Americans in Science chapter), contributed research for policy initiatives at the Cincinnati Health Department (Health in All Policy Fact Sheets), and engaged the community through outreach (Brain Awareness Week).

After graduating she completed a science policy fellowship at Research!America, a non-profit that specializes in advocating for funding for research to accelerate medical progress. There, she provided support and expert advice on translating scientific findings to compelling messaging for cross-relational research advocacy efforts and congressional outreach. Notably, she facilitated a collaboration with the National Science Policy Network's #BlackInSciPolWeek on Twitter, curating a collection of videos that featured a number of preeminent Black science policy professionals. She hopes that these examples of visual representation will inspire the next generation of science policy leaders.

Currently, Dr. Miles is taking active rest and serving as the Community Features Coordinator for Vanguard STEM, an online community that celebrates, honors, protects and amplifies the voices of women of color in STEM via curated digital content and intentional messaging. In addition, Dr. Miles volunteers as a museum docent at the Reginald F. Lewis Museum, the largest African American history museum in Maryland. In her free time, Dr. Miles enjoys art galleries, thrifting, and networking.

ANDREA D. MORGAN, Graduate Research Assistant, Behavioral and Systems Neuroscience Program, Oregon Health & Science University

Andrea Morgan is from Southern California, where she started off in addiction research in a master's program. Because she was living in a ghetto, she became very interested in pain, trauma, and the overlap in the structures/systems involved in all three research areas. That ultimately led her to Oregon Health & Science University, where she's currently a 4th year student in the Behavioral and Systems Neuroscience program. Her

current program is heavily focused on addiction and trauma/stress, so she continues to learn about the neurological processes involved in both and is able to apply certain concepts to the pain field. However, she's found her place in science in investigating non-somatic influences (e.g., light, scent) on descending pain modulation in the context of chronic pain disorders using behavioral assays and immunohistochemistry. She also collaborates with electrophysiologists to identify underlying neural circuitry that may eventually be targeted in drug design. Her expertise is in natural rodent behavior, use of behavioral assays in a lab setting, and likely (but unintentional) factors that ultimately impact results.

JANETTE NESHEIWAT, MD, Medical Director at CityMD, Fox News Medical Contributor

Dr. Janette Nesheiwat is a top Family and Emergency Medicine doctor. She brings a refreshingly no-nonsense attitude to the latest medical news, breaking down everything you need to know to keep you and your family healthy at all times.

Whether caring for her patients in the ER, serving on the front lines of disaster relief with the Red Cross, or sharing need-to-know info with TV audiences, Dr. Nesheiwat's mission is not only to save lives, but to change them, by giving real people the treatment and the expertise they need.

Her sincere and straightforward approach is a product of her background. She was one of five kids raised by a widowed mother, and also completed U.S. Army ROTC Advanced Officer Training in Ft. Lewis, Washington prior to becoming a Family and Emergency Physician. She has led medical relief missions around the globe and today she is a medical news correspondent and the Medical Director at CityMD.

ESTHER C. NOLTON, PhD, MEd, Program Officer, Evaluation and Analysis, Patient-Centered Outcomes Research Institute

Esther C. Nolton, PhD, Med (she/her), is a Program Officer in the Evaluation and Analysis department at the Patient-Centered Outcomes Research Institute (PCORI). Before joining PCORI, Nolton previously served as the Director of Clinical Research at Inova Sports Medicine, then worked as a consultant providing research, evaluation, and technical assistance services for several federal agencies. Nolton is an experienced sports medicine clinician and researcher and has authored several publications related to neuromuscular biomechanics, athletic training professional practice, orthopedic surgery techniques, and health quality and functional measurement. She has taught sports medicine, functional anatomy, research methods, evidence-based medicine, and program evaluation at George Mason University and the Virginia Commonwealth University School of Medicine.

Nolton has an established background in methodology, evaluation, and facilitation with specializations in quantitative measurement, survey, and qualitative methodologies. She also has experience facilitating strategic planning, organizational learning, and evaluation policy processes primarily from her work as an American Evaluation Association Graduate Education Diversity Internship Scholar with the Evaluation and Assessment Capacity Section at the National Science Foundation. Nolton continues to be committed to studying social determinants of health and education, policy and program evaluation, evaluation practice and

policy, research and evaluation methodology, democratizing evidence utilization, evidence-based policymaking, and organizational behavior.

Nolton received a Bachelor of Science in Athletic Training with minors in Psychology and Biology from George Mason University, a Master's in Education in Kinesiology with a focus in Sports Medicine from the University of Virginia, and a PhD in Research & Evaluation Methods with a secondary specialization in Health & Education Policy from George Mason University. Her doctoral dissertation was an ethnographic study titled, "Mapping the Institutionalization of Evaluation in the US Federal Government," which investigated the factors and contexts that have influenced the organizational culture and capacity for evaluation and other evidence-building activities.

SETHURAMAN PANCHANATHAN, PhD, Director, National Science Foundation

The Honorable Sethuraman Panchanathan is a computer scientist and engineer and the 15th director of the U.S. National Science Foundation (NSF). NSF is an \$8.5B independent federal agency and the only government agency charged with advancing all fields of scientific discovery, technological innovation, and STEM education.

Dr. Panchanathan has a distinguished career in science, technology, engineering, and education that spans more than three decades. He served as executive vice president of the Arizona State University Knowledge Enterprise, where he also founded the Center for Cognitive Ubiquitous Computing. Prior to becoming director of NSF, Panchanathan served on the National Science Board for six years and has also served on and chaired numerous high-level research and innovation organizations. He is a fellow of the National Academy of Inventors, the American Association for the Advancement of Science, the Association for Computing Machinery, and other prestigious science and engineering organizations. Dr. Panchanathan's scientific contributions have advanced the areas of human-centered multimedia computing, haptic user interfaces, person-centered ubiquitous computing technologies for empowering individuals with a range of abilities.

SUDIP PARIKH, PhD, CEO, American Association for the Advancement of Science; Executive Publisher, Science Family of Journals

Sudip Parikh, PhD, became the 19th chief executive officer of the American Association for the Advancement of Science (AAAS) and executive publisher of the Science family of journals in January 2020. Parikh has spent two decades at the nexus of science, policy, and business.

Immediately prior to joining AAAS, Dr. Parikh was senior vice president and managing director at DIA Global, a neutral, multidisciplinary organization bringing together regulators, industry, academia, patients, and other stakeholders interested in healthcare product development. He led strategy in the Americas and oversaw DIA programs that catalyzed progress globally toward novel regulatory frameworks for advanced therapies not amenable to existing regulations. Prior to DIA, Sudip was general manager of the Health and Consumer Solutions business unit and vice president at Battelle, a multibillion-dollar research and development organization. He led a \$150 million business unit with over 500 scientific, technical, and computing experts performing basic and applied research, developing medicines and healthcare devices, and creating advanced analytics and artificial intelligence applications to improve human health. Previously, Parikh led Battelle's

global AgriFood business unit. Headquartered in London and Geneva, this unit provided environmental fate research and agriculture product development services from laboratories throughout Europe and the United States.

From 2001 to 2009, Parikh served as science advisor and professional staff to the United States Senate Appropriations Committee, where he was responsible for negotiating budgets for the National Institutes of Health (NIH), Centers for Disease Control and Prevention, Agency for Healthcare Research and Quality, Biomedical Advanced Research and Development Authority, and other scientific and health agencies. A key legislative liaison to the research and development ecosystem, Parikh was on the frontlines of many science policy issues debated during that time, including embryonic stem cell research, cloning, disease surveillance, bioterrorism, cyber security, and doubling the NIH budget.

An active member of the scientific advocacy community, Parikh serves as a board member and officer for several impactful organizations, including Research!America, Friends of Cancer Research, and ACT for NIH. He has received multiple public service awards, including recognition from the American Association of Immunologists, the National AIDS Alliance, the Coalition for Health Services Research, and the Juvenile Diabetes Research Foundation. Sudip is committed to early STEM education and, as a parent of three energetic young children, he prioritizes volunteering as a mentor for Science Olympiad teams at two elementary schools. Early in his career, Parikh was a Presidential Management Intern at the NIH. He was awarded a National Science Foundation Graduate Research Fellowship while earning his PhD in macromolecular structure and chemistry from the Scripps Research Institute in La Jolla, Calif. There, he used structural biology and biochemistry techniques to probe the mechanisms of DNA repair enzymes bound to DNA. The son of Indian immigrants who worked in the textile and furniture manufacturing plants of North Carolina, Parikh completed undergraduate studies at the University of North Carolina at Chapel Hill, first as a journalism major before switching into materials science.

ALOK PATEL, MD, Pediatric Hospitalist, Lucile Packard Children's Hospital; Special Correspondent, ABC News; Pediatric Content Advisor, MedScape; Host, NOVANow Podcast, PBS

Dr. Alok Patel is a physician, host, journalist, and producer who firmly believes relatability should drive science communication. "Scientists," he'll tell you, "need a much louder megaphone." He is a special correspondent for ABC News and regularly appears as an on-camera expert for several news outlets. Additionally, he is a co-host of "Parentalogue," a digital series from NOVA and PBS Digital Studios, and hosts the podcast NOVA Now and a popular web series for Medscape, "the Hospitalist Retort." Previously, he worked as a medical producer for CNN/HLN and as a host/contributor for both ABC and NBC News in New York. He is involved with several advocacy projects, including a media-based sex trafficking education campaign, a 501(c)(3) dedicated to improving healthcare's presence on social media on initiatives to improve access to mental health care, and serves on the board of advisors for WebMD. Dr. Patel is originally from Arizona, completed his pediatric residency at Seattle Children's Hospital, and is currently faculty as a pediatric hospitalist at Stanford University and the University of California, San Francisco.

In his rare downtime, you can catch him practicing martial arts, creating cocktails, discovering new music (ask him about this), getting bossed around by his infant daughter, or spending time with his wife, a renowned wedding/event planner, who is more creative, talented, and far better-looking than he is.

LAUREN POWELL, MPA, PhD, President & CEO, The Equitist, LLC; Vice President, U.S. Health Equity & Community Wellness, Takeda Pharmaceuticals

Recently named among Fortune's 40 Under 40 in Healthcare, Dr. Lauren Powell is the President & CEO of The Equitist, LLC and concurrently serves as the Vice President, U.S. Health Equity & Community Wellness for Takeda Pharmaceuticals. In this role she spearheads efforts to drive health equity through building trust, and investing in building generational community wellness in diverse under-resourced communities across the U.S.

For more than a decade, Dr. Powell has been immersed in broad and progressive leadership positions where she's been unapologetically outspoken about racial injustices and health inequities. Her professional and personal experiences spearheading equity efforts in healthcare, state government, academia, and public health, make her a nationally sought after leader, speaker, and consultant on all things health equity.

Formerly the Director of Health Equity for the Commonwealth of Virginia, Dr. Powell was the youngest Black woman and the first with a PhD to serve in this powerful role where she led statewide strategic plans and initiatives towards pushing Virginia's 8.5 million residents closer to health equity.

Dr. Powell has an established track record as a community-engaged, social epidemiologist with doctoral training on leveraging data for equity. She earned a Master in Public Administration at the Harvard Kennedy School of Government, and a Doctor of Philosophy in Clinical and Population Health Research at the University of Massachusetts Medical School. Dr. Powell deeply values mentorship and community engagement. She actively seeks opportunities to help mold and encourage the next generation of leaders in health equity.

Prior to her graduate school matriculation, she held positions coordinating clinical research studies at a number of prestigious medical institutions including The Johns Hopkins Schools of Medicine and Public Health, the Dana Farber Cancer Institute, and the National Cancer Institute at the National Institutes of Health.

Dr. Powell has been featured on several national and international news sources and outlets including: Marie Claire, Politico, The Guardian, Huffington Post, NPR, BBC, CNBC, PBS NewsHour, NowThis, Newsy, and Cheddar.

GUILLERMO J. PRADO, PhD, Vice Provost, Faculty Affairs; Dean, Graduate School; Professor, Nursing and Health Studies, Public Health Sciences, and Psychology; University of Miami

Dr. Guillermo (Willy) Prado is Vice Provost for Faculty Affairs; Dean of the Graduate School; and Professor of Nursing and Health Studies, Public Health Sciences, and Psychology at the University of Miami. His research broadly focuses on the development, evaluation, and dissemination of parenting interventions for Hispanic

youth and their families. Prado's research has appeared in over 140 peer-reviewed articles and chapters. He has been PI, Co-I, mentor, or consultant of over \$100 million dollars of NIH. His research has been recognized by numerous organizations, including the National Hispanic Science Network, the Society for Prevention Research, and the Society for Adolescent and has been featured in several domestic and international news outlets, including the Miami Herald, NBC, and CNN en Español. Prado is currently the Director of the Investigator Development Core of the NIH funded Center for Latino Health Research Opportunities. He is also the President of the Society for Prevention Research; a member of the National Academies of Sciences, Engineering, and Medicine's Committee on Prevention and Control of Sexually Transmitted Diseases in the United States; and a Board Member of Research!America.

PETER PRONOVOST, MD, PhD, Chief Quality & Clinical Transformation Officer, University Hospitals; Professor, Department of Anesthesiology and Critical Care Medicine, School of Medicine and School of Nursing, Case Western Reserve University

Peter Pronovost, MD, PhD, is a world-renowned patient safety champion, innovator, critical care physician, a prolific researcher (publishing over 800 peer review publications), entrepreneur (founding a healthcare start-up that was acquired), and a global thought leader, informing U.S. and global health policy. His scientific work leveraging checklists to reduce catheter-related bloodstream infections has saved thousands of lives and earned him high-profile accolades, including being named one of the 100 most influential people in the world by Time Magazine, receiving a coveted MacArthur Foundation "genius grant" in 2008.

Dr. Pronovost currently serves as the Chief Quality & Clinical Transformation Officer for University Hospitals, a comprehensive health system with a national reputation for providing world class healthcare, research and education. Headquartered in Cleveland, University Hospitals has annual revenues of \$4.4 billion, 20 hospitals, more than 50 health centers and outpatient facilities, and over 200 physician offices located throughout 16 counties.

As Chief Quality & Clinical Transformation Officer, Dr. Pronovost is charged with fostering ideation and implementation for new protocols to eliminate defects in value and thereby enhance quality of care; developing new frameworks for population health management for UH's more than one million patients; and managing the UH Accountable Care Network – one of the nation's largest – comprising more than 581,000 members. In this role, Dr. Pronovost leads the system in championing a new narrative that focuses on Keeping People Healthy at Home. Utilizing his previously successful concept of checklists, Dr. Pronovost created a new list of key principles for eliminating defects in value and has incorporated the framework into an analytic platform integrating claims, electronic medical record (EMR), and scheduling data, to make defects in value visible to clinicians. In just 12 months, this work fueled a reduction in annual costs per patient in the UH ACO by 9 percent. Dr. Pronovost also serves as a Professor in the Department of Anesthesiology and Critical Care Medicine at the Case Western Reserve University School of Medicine and School of Nursing.

Previously, Dr. Pronovost served as the Senior Vice President for Patient Safety and Quality at Johns Hopkins Medicine as well as the founder and director of the Johns Hopkins Medicine Armstrong Institute for Patient

Safety and Quality. In this role, he worked to eliminate all harms in one health system following on his success in eliminating one harm in most health systems across the U.S. Dr. Pronovost also served as the Senior Vice President for Clinical Strategy and the Chief Medical officer for UnitedHealthcare. Dr. Pronovost was elected to the National Academy of Medicine in 2011, elected as Fellow of the American Academy of Nursing and has received multiple honorary degrees. Dr. Pronovost is an advisor to the World Health Organizations' World Alliance for Patient Safety and regularly addresses the U.S. Congress on patient safety issues. In response to a White House executive order, Dr. Pronovost co-chaired the Healthcare Quality Summit to modernize the Department of Health and Human Services quality measurement system.

Dr. Pronovost earned his medical degree from Johns Hopkins University School of Medicine in Baltimore. He completed his anesthesiology and critical care medicine residency as well as a fellowship in critical care medicine at Johns Hopkins Hospital. He earned his PhD in Clinical Investigation from the Johns Hopkins School of Hygiene and Public Health.

GARY PUCKREIN, PhD, President and CEO, National Minority Quality Forum

Dr. Gary Puckrein is the founding President and Chief Executive Officer of the National Minority Quality Forum (NMQF), a 501(c)(3) not-for-profit research and advocacy organization headquartered in Washington, DC.

The mission of NMQF is to reduce patient risk by assuring optimal care for all. NMQF's vision is an American health services research, delivery, and financing system whose operating principle is to reduce patient risk for amenable morbidity and mortality while improving quality of life. Dr. Puckrein received his doctorate from Brown University.

JAMES P. QUINN, PhD, Neurology Research Fellow, Alzheimer's Clinical & Translational Research Unit (ACTRU), Massachusetts General Hospital and Harvard Medical School

James Quinn is a neurology research fellow in the Alzheimer's Clinical & Translational Research Unit (ACTRU) at Massachusetts General Hospital and Harvard Medical School under the supervision of Dr. Becky Carlyle and Dr. Steven Arnold. His research involves studying the neuronal signaling molecules, neuropeptides, in dementia pathogenesis to unravel disease mechanisms, identify new diagnostic biomarkers, and define novel therapeutic targets. He has recently started a new project characterizing novel TDP-43 antibodies as a diagnostic biomarker of amyotrophic lateral sclerosis in collaboration with AC-Immune. His PhD research at the University of Manchester in the UK focused on the role of tau proteolysis in dementia pathogenesis, identifying granzyme A as a novel protease of tau and characterizing cellular effects of tau fragments and their role in the brains of patients with dementia. James is passionate about community engagement and public outreach of scientific research. He also works to improve the landscape for early career researchers with the Alzheimer's Association. When he isn't in the lab you can find him exploring the U.S. and the world (when allowed), cycling, bouldering and listening to live music.

CHETANA RAO, PhD, Head, Site Strategy and Operations, Redwood City, San Francisco, Bristol Myers Squibb

Chetana Rao, PhD serves as the head of Site Strategy and Operations within Bristol Myers Squibb's Redwood City and San Francisco sites, where she manages operations in multiple cross-functional business areas including finance, accounting and administration. She also leads Diversity & Inclusion initiatives for the two BMS sites in the Bay Area, where she is focused on building a diverse workforce and fostering an inclusive company culture.

Chetana holds a seat on the BMS STEM Council and has been instrumental in launching BMS' STEM program in the Bay Area. In California, the company supports local initiatives for students from kindergarten through graduate school that help expose students to STEM subjects, ignite and sustain their curiosity about science and provide resources to help them pursue academic and career interests in STEM. The program aims to nurture the next generation of young scientists while also providing access to equal opportunities for students in historically excluded communities who have a passion for science.

"I want to invest now in these kids and these schools so that we as a society can reap the benefits five to 10 to 20 years from now," Chetana says. "Such an investment not only supports our mission to help patients prevail over serious diseases, but also benefits the community as a whole making science accessible to underrepresented minorities, offering exciting careers in science, and nurturing talent as one of the key resources for our future."

Chetana joined Bristol Myers Squibb in 2009 and has more than 20 years of experience in the world of drug discovery in antibody drug conjugation, antibody discovery, protein chemistry and biotechnology. She has a well-established scientific record, consisting of more than 20 papers in peer-reviewed journals and more than 25 global patents.

Chetana earned her PhD in Biochemistry and Molecular Biology from the University of Florida, where she earned the Best Thesis Award from the College of Medicine. She worked as a postdoctoral scientist at the University of Florida and the University of California Davis.

DEREK RAPP, Managing Director, RiverVest Venture Partners

Derek Rapp joined RiverVest in 2019, bringing broad healthcare experience, along with strong entrepreneurial, deal-making, and strategic skills. In addition to being involved in RiverVest's investment process, Derek works closely with the management team on strategy, operations, fundraising and investor relations. He also serves as liaison to the St. Louis region's growing innovation system.

Prior to RiverVest, Derek served as president & CEO of JDRF, the world's largest non-government funder of diabetes research and a major advocacy group for the type 1 diabetes community, and as CEO for life sciences start-up Divergence, Inc., which he led to a successful exit. He also served as Monsanto Company's head of mergers and acquisitions, where he led transactions totaling more than \$7 billion, and as the company's

director of investor relations. Derek began his career in mergers and acquisitions with Lazard Freres & Co. in New York.

Derek is a current member of the board of directors and the executive committee of Research!America and a member of the Global Mission Board of JDRF. He has served on numerous other boards, including chairing each of the Greater Saint Louis Community Foundation Board of Directors, the Plant and Life Sciences Working Group in St. Louis, and the Donald Danforth Plant Science Center Friends Board.

Derek earned an MBA from the Wharton School of the University of Pennsylvania and an BA from Brown University.

DAVID M. REESE, MD, Executive Vice President, Research and Development, Amgen

Dr. David M. Reese is executive vice president, Research and Development. In this role, Dr. Reese oversees Discovery Research, Global Development, Global Regulatory Affairs and Safety, as well as Global Medical. Dr. Reese joined Amgen in 2005 and has served in various leadership roles within the Research and Development organization. This includes most recently serving as Senior Vice President of Translational Sciences and Oncology where he oversaw the translation of Amgen's medicines from the lab into the clinic and the overall oncology strategy.

Prior to joining Amgen, Dr. Reese was director of Clinical Research for the Breast Cancer International Research Group (BCIRG) and a co-founder, president and chief medical officer of Translational Oncology Research International (TORI), a not-for-profit academic clinical research organization. Dr. Reese is a graduate of Harvard College and the University of Cincinnati College of Medicine. He completed training in Internal Medicine and Hematology/Oncology at the University of California, Los Angeles (UCLA) School of Medicine, and subsequently served on the faculty at UCLA and the University of California, San Francisco.

MARK REISENAUER, President, Astellas Pharma US

Mark Reisenauer is President, Astellas Pharma US. In this role, he is responsible for the operations of Astellas Pharma across the U.S., a \$4 billion affiliate of the Tokyo-based pharmaceutical company headquartered in Northbrook, Illinois, with 1,200 employees. Astellas is a company dedicated to improving the health of people around the world through the provision of innovative pharmaceutical products.

Reisenauer was most recently Senior Vice President of Astellas' Oncology business unit and joined Astellas in 2011 as Vice President of Oncology Sales and Marketing. During his tenure, Mark's leadership has yielded the fastest-growing franchise in Astellas' U.S. portfolio, as Oncology franchise sales grew from less than 10 percent of sales to approximately 50 percent of U.S. sales. He has been instrumental in bringing many new important oncology treatments to patients, including XTANDI® (enzalutamide), XOSPATA® (gilteritinib) and PADCEV™ (enfortumab vedotin-ejfv). All three products have become standards of care in their approved indications.

Prior to joining Astellas, Reisenauer served as Senior Vice President and Chief Commercial Officer of Micromet Inc. (now part of Amgen), where he led investor and public relations, new product planning, and commercial launch planning. Previously, Reisenauer held various sales and marketing leadership roles at AstraZeneca, Bristol Myers Squibb, Pharmacia, and Abbott. Reisenauer earned a bachelor's degree in political science from the University of Wisconsin.

Reisenauer serves on the board of the Pharmaceutical Research and Manufacturers of America (PhRMA), an organization dedicated to advancing policies that ensure continued investment in biopharmaceutical innovation.

AMY COMSTOCK RICK, JD, President and CEO, Food and Drug Law Institute

Amy Comstock Rick, J.D., is the President and Chief Executive Officer of the Food and Drug Law Institute (FDLI), having joined in August 2014. FDLI is a non-profit organization dedicated to providing an innovative, open, balanced exchange of ideas and viewpoints across the field of food and drug law. FDLI's mission is to provide topical and timely education, training, and publications, foster professional relationships, and to act as a liaison to inform public policy, law, and regulation. Prior to joining FDLI, Ms. Rick was the Chief Executive Officer of the Parkinson's Action Network (PAN) from 2003-2014. PAN is a Washington D.C.-based national nonprofit focused on educating the public and government leaders on better policies for research and therapy development and an improved quality of life for people living with Parkinson's disease. Ms. Rick has also served as the President of the Coalition for the Advancement of Medical Research, on the NIH Institute for Neurological Disorders and Stroke's Advisory Council, and on the Boards of Directors of the National Health Council and the American Brain Coalition. Before joining PAN, she was the Senate-confirmed Director of the U.S. Office of Government Ethics from 2000-2003 and the Associate Counsel to the President in the White House Counsel's Office from 1998-2000. Ms. Rick began her federal service as a career attorney at the U.S. Department of Education in 1989 and became the Assistant General Counsel for Ethics in 1993. Prior to her government service, Ms. Rick was an associate attorney at the law firm of Beveridge & Diamond. She received a Bachelor of Arts degree from Bard College and a Juris Doctor degree from the University of Michigan.

RANDALL "RANDY" RUTTA, CEO, National Health Council

Randall "Randy" Rutta is a senior health care executive dedicated to policy-to-practice solutions that interpret, influence, and improve federal and state health care policies to enhance public and private sector health care innovation, outcomes, and efficiency.

Rutta joined the National Health Council (NHC) in February 2021 as the organization's Chief Executive Officer. As CEO, Rutta leads the NHC, as it enters its second century, with the goal of affecting change across the entire health system and promoting increased access to affordable, high-value, sustainable health care. The NHC brings diverse organizations together to forge consensus and drive patient-centered health policy, and Rutta inspires the NHC staff to implement a Broad-driven strategic plan and public policy and advocacy efforts.

Prior to joining the NHC, Rutta was the President & CEO of the American Autoimmune Related Disease Association (AARDA), a national organization dedicated to addressing the problem of autoimmunity, the major cause of more than 100 serious chronic diseases. AARDA initiated and hosts the 40-member National Coalition of Autoimmune Patient Groups and is a longtime member of the NHC. Prior to his role as President & CEO, he served as AARDA's Federal Policy Consultant since March 2018.

Rutta served as Principal at ConnectHealth, LLC a Washington, DC-based consulting services company that he established in 2017 to provide strategic insight and support in achieving objectives across the health care ecosystem.

In 2017, Rutta transitioned from the position of President and CEO at Easterseals, a global nonprofit organization dedicated to the health, well-being, and success of people with disabilities, veterans, seniors, and families. For most of his 36 years at Easterseals, he was located in Washington, DC, at the organization's Office of Public Affairs, overseeing federal and state legislative and regulatory activities, federal grant development, and international knowledge exchange. His career experience has been in acute care, health care quality assurance, and health policy development and implementation.

Rutta currently chairs the Board of the Partnership to Fight Chronic Disease (PFCD), a national coalition of nearly 100 patient, provider, and community organizations, business and labor groups, and health policy experts committed to raising awareness of chronic disease in America and globally. He has been involved with PFCD as a partner organization leader and board member since 2007. He also is a Vice President and Secretary of American Eagle Lifecare Corporation and has been a member of its Board of Directors since 2008.

Rutta holds a Master of Arts in Politics, focusing on international health policy, from Catholic University of America in Washington, DC, and a Bachelor of Arts in Sociology from the University of Minnesota in Minneapolis.

MARIA RYAN, DDS, PhD, Vice President and Chief Clinical Officer, Colgate-Palmolive Company

Maria Emanuel Ryan, DDS, PhD is Vice President and Chief Clinical Officer at the Colgate-Palmolive Company where she provides oversight and leadership to dental and dermal clinical organizations, knowledge management, scientific communications, biosolutions and methods development teams. Dr. Ryan previously served as Professor and Chair of the Department of Oral Biology and Pathology at Stony Brook University where she was actively involved in teaching, clinical practice and research. She is the Past President of the American Association for Dental Research (AADR) and has served on many academic and foundation boards. Dr. Ryan has received numerous awards including NIH National Research Service Awards and a Physician Scientist Award. She was the recipient of the New Dentist Leadership Award from the Dental Society of the State of New York and received an achievement award from the American Dental Association. Dr. Ryan was the first recipient of the Victress Health Award which she received in Berlin, Germany in 2010 to recognize her educational and research efforts in the area of women's health. Dr. Ryan is a Distinguished Alumnus of Stony Brook's School of Dental Medicine and was a Fellow of the Hedwig van Ameringen Executive Leadership in

Academic Medicine (ELAM) Program for Women at Drexel University College of Medicine. Dr. Ryan is a nationally and internationally known speaker and author who has appeared on multiple media outlets to discuss the role of the dental professional in the provision of optimal overall health care.

ROBERT SELLERS, PhD, Vice Provost for Equity & Inclusion and Chief Diversity Officer, Charles D. Moody Collegiate Professor of Psychology, University of Michigan

Robert M. Sellers, received his Bachelor of Science degree in Psychology from Howard University and his doctorate in personality Psychology from the University of Michigan. He is responsible for overseeing the University's five-year strategic plan for diversity, equity and inclusion, and serves as a principal adviser to the President as a member of the University's executive leadership team. Dr. Sellers works with the Provost on matters related to diversity at the University as well as a broad range of academic issues including the budget, faculty tenure and promotions, and student enrollment. He oversees operations of three central administrative units. Dr. Sellers provides strategic leadership to increase access and success for all students, recruit and retain diverse faculty, and develop academic programs that prepare all students for success in a diverse world. Prior to joining the Provost's Office, Dr. Sellers was chair of the University of Michigan Department of Psychology. His research interests include ethnicity, racial and ethnic identity, personality and health, athletic participation, and personality. He has published several research articles and book chapters that examine factors associated with the psycho-social development of African American student-athletes.

FRANK SESNO, Director of Strategic Initiatives, The George Washington University School of Media and Public Affairs

Frank Sesno served as director of the School of Media and Public Affairs at the George Washington University for 11 years. He is now the Director of Strategic Initiatives. He is an Emmy Award-winning journalist and creator of Planet Forward, a user-driven web and television project that highlights innovations in sustainability. He hosts and facilitates the Planet Forward Salon Series focusing on topics such as energy policy, green jobs and food production. He has moderated events for the American Association for the Advancement of Science, Bayer CropScience, Land O'Lakes Foundation and National Geographic, among others.

As SMPA director, Sesno led a faculty of nearly two dozen world-class professors who research and teach journalism, political communication and the impact of digital media in international affairs. Sesno taught classes on environmental multimedia reporting, ethics in journalism, documentary and "the art of the interview."

Inspired by his mother's experience with Hospice, Sesno hosted the Hospice Foundation of America's Continuing Education Series for seven years. Sesno's diverse career spans more than three decades, including 21 years at CNN where he served as White House correspondent, anchor and Washington Bureau Chief. He has covered a diverse range of subjects, from politics and conventions to international summits and climate change. He has interviewed five U.S. presidents and thousands of political, business and civic leaders – ranging from Hillary Clinton and Israeli Prime Minister Benjamin Netanyahu to Microsoft founder Bill Gates and broadcast legend Walter Cronkite.

Before joining CNN in 1984, Sesno worked as a radio correspondent at the White House and in London for the Associated Press. He has won several prestigious journalistic awards, including an Emmy, several cable ACE awards, and an Overseas Press Club Award. Sesno is a member of the board of trustees at Middlebury College, a member of the National Advisory Board for the Poynter Institute, a member of the Council on Foreign Relations and a board member at the National Council for Science and the Environment and at AmeriCares. He has a Bachelor of Arts degree in American History from Middlebury College.

THE HONORABLE DONNA SHALALA, PhD, Professor, University of Miami; U.S. Secretary of Health and Human Services, 1993-2001; U.S. Representative, 2019-2021

The Honorable Donna Shalala served as Secretary of Health and Human Services (1993-2001) in the Clinton Administration. She also served in the U.S. House of Representatives (2019-21) and as Assistant Secretary for Policy Development and Research at the U.S. Department of Housing and Urban Development in the Carter Administration (1979-1970). One of the most honored academics of her generation, Dr. Shalala served as President of the University of Miami, President of Hunter College of the City University of New York and Chancellor of the University of Wisconsin-Madison. In 2007, President George W. Bush handpicked Shalala to co-chair with Senator Bob Dole the Commission on Care for Returning Wounded Warriors, to evaluate how wounded service members transition from active duty to civilian society. In 2009 she was appointed chair of the Committee on the Future of Nursing at the Institute of Medicine of the National Academy of Sciences. President Bush presented her in 2008 with the Presidential Medal of Freedom, the nation's highest civilian award. Secretary Shalala has been elected to seven national academies: National Academy of Education, the National Academy of Public Administration, the American Academy of Arts and Sciences, the American Philosophical Society, the National Academy of Social Insurance, the American Academy of Political and Social Science, and the National Academy of Medicine. She earned her PhD degree from The Maxwell School of Citizenship and Public Affairs at Syracuse University.

NED SHARPLESS, MD, Director, National Cancer Institute, NIH

Norman E. "Ned" Sharpless, MD, was officially sworn in as the 15th director of the National Cancer Institute (NCI) on October 17, 2017. Prior to his appointment, Dr. Sharpless served as the director of the Lineberger Comprehensive Cancer Center at the University of North Carolina (UNC).

Dr. Sharpless was a Morehead Scholar at UNC-Chapel Hill and received his undergraduate degree in mathematics. He went on to pursue his medical degree from the UNC School of Medicine, graduating with honors and distinction in 1993. He then completed his internal medicine residency at the Massachusetts General Hospital and a hematology/oncology fellowship at Dana-Farber/Partners Cancer Care, both of Harvard Medical School in Boston. After 2 years on the faculty at Harvard Medical School, he joined the faculty of the UNC School of Medicine in the Departments of Medicine and Genetics in 2002. He became the Wellcome Professor of Cancer Research at UNC in 2012.

Dr. Sharpless is a member of the Association of American Physicians and the American Society for Clinical Investigation, and is a Fellow of the Academy of the American Association of Cancer Research. He has authored more than 160 original scientific papers, reviews, and book chapters, and is an inventor on 10 patents. He cofounded two clinical-stage biotechnology companies: G1 Therapeutics and Sapere Bio (formerly HealthSpan Diagnostics). He served as Acting Commissioner for Food and Drugs at the US FDA for seven months in 2019, before returning to the NCI Directorship.

FAIZA SIDDIQUI, PhD, Research Associate, Department of Internal Medicine, University of South Florida

Faiza Siddiqui, PhD, received her Bachelor's and Master's in biotechnology in Delhi, India. She worked as a postdoctoral fellow at the Pennsylvania State University for 3 years followed by 2 years of postdoctoral training at University of South Florida. She is currently working as a Research Associate in the Department of Internal Medicine at University of South Florida. She has spent more than a decade studying the bug that causes malaria. It amazes her every day how intelligent this tiny parasite is and how smartly it evades all our check points for malaria control. She is passionately hopeful that one day together we will be able to eliminate it completely. Apart from research, what interests her is science communication and how essential it is to relay the message of science to the common people.

LISA SIMPSON, MB, BCh, MPH, FAAP, President and CEO, AcademyHealth

Dr. Lisa Simpson has been the President and Chief Executive Officer of AcademyHealth since 2011. A nationally recognized health policy researcher and pediatrician, she is a passionate advocate for the translation of research into policy and practice. Her research, and over 100 articles and commentaries in peer reviewed journals, focuses on the role of evidence and data to improve health and healthcare, particularly for children and vulnerable populations.

Before joining AcademyHealth, Dr. Simpson spent eight years as a professor of pediatrics, first as an Endowed Chair in Child Health Policy at the University of South Florida and then as the Director of the Child Policy Research Center at Cincinnati Children's Hospital Medical Center and the University of Cincinnati. She served as the Deputy Director of the Agency for Healthcare Research and Quality from 1996 to 2002. Dr. Simpson serves on the Board of Directors of the Institute for Accountable Care and the National Health Council and the Editorial Board of HSR. In October 2013, Dr. Simpson was elected to the National Academy of Medicine (formerly the Institute of Medicine) and was awarded an honorary Doctor of Science degree by the Georgetown University School of Nursing and Health Studies in 2013.

JOHN SINIFF, Executive Vice President, Subject Matter; Former Opinion Editor, USA Today

John Siniff is a veteran journalist who brings a newsroom's approach and perspective to Subject Matter's diverse campaigns and content. He works with clients across an expansive menu of issues and needs, whether

developing effective content strategy or directing executive communications. John specializes in storytelling that is authentic, informative, persuasive and actionable. A graduate of the University of Texas at Austin, John began his career as an editor in El Paso before moving to USA Today in Washington. In his 20-year career at USA Today, John was Page One Editor and Cover Story Editor, shaping the daily coverage across USA Today's print and digital platforms. John also directed the Op-Ed Page for nearly a decade while serving on the newspaper's Editorial Board, thus helping to guide and inform wide-ranging debates on the issues of the day. John's work—some his bylines, some written for clients—has appeared in The New York Times, The Washington Post, USA Today, CNN, Time, Newsweek, Fortune and Art News, among others. He loves cooking, gardening and good wine but has a strong aversion to buzzwords. He's married with three young boys and a 6-month-old pandemic pup in Northern Virginia.

MEG TIRRELL, Senior Health and Science Reporter, CNBC

Meg Tirrell is CNBC's senior health and science reporter. Since joining CNBC in 2014, Tirrell has covered the development of new medicines for Alzheimer's, cancer and rare diseases, and tracked public health emergencies from Ebola to Zika to the COVID-19 pandemic. Her reporting has also chronicled the massive set of trials seeking to hold the drug industry accountable for the opioid epidemic, market failures that have led to life-threatening drug shortages, and the ongoing fight over the cost of medicines. Prior to joining CNBC, Tirrell covered the biotechnology industry for Bloomberg News, where she also contributed to Bloomberg Television and Bloomberg Businessweek. Tirrell holds a master's degree in journalism from Northwestern University and a bachelor's degree in English and music from Wellesley College. Follow her on Twitter @megtirrell.

THE HONORABLE FRED UPTON, U.S. Representative (R-MI-06)

Congressman Fred Upton is proud to represent the common sense values of Southwest Michigan's Sixth Congressional District. A champion for bipartisan solutions, Fred Upton is Vice Chair of the House Problem Solvers Caucus. From 2010 to 2016, Fred was selected by his House colleagues to serve as Chairman of the Energy and Commerce Committee, and today, he serves as the top Republican on the Energy Subcommittee. In 2014, along with U.S. Rep. Diana DeGette from Colorado, Fred launched the 21st Century Cures initiative. This bipartisan effort aims to bring researchers, industry, and patients together to speed up the discovery, development, and delivery of life-saving cures. Most recently, Fred and Rep. DeGette unveiled their highly-anticipated Cures 2.0 legislation to build upon their tremendous success with 21st Century Cures and find treatments to some of the world's cruelest diseases from cancer to Alzheimer's. Fred has a reputation of fighting for issues important to folks at home, like protecting our Great Lakes, ensuring safe drinking water, and addressing the opioid epidemic. Fred's priorities for today remain the same as when he was first elected in 1986 – job creation, economic growth, and working to help all residents of Southwest Michigan live longer, better lives.

ROCHELLE WALENSKY, MD, MPH, Director, Centers for Disease Control and Prevention

Rochelle P. Walensky, MD, MPH, is the 19th Director of the Centers for Disease Control and Prevention and the ninth Administrator of the Agency for Toxic Substances and Disease Registry. She is an influential scholar

whose pioneering research has helped advance the national and global response to HIV/AIDS. Dr. Walensky is also a well-respected expert on the value of testing and treatment of deadly viruses.

Dr. Walensky served as Chief of the Division of Infectious Diseases at Massachusetts General Hospital from 2017-2020 and Professor of Medicine at Harvard Medical School from 2012-2020. She served on the frontline of the COVID-19 pandemic and conducted research on vaccine delivery and strategies to reach underserved communities. Dr. Walensky is recognized internationally for her work to improve HIV screening and care in South Africa and nationally recognized for motivating health policy and informing clinical trial design and evaluation in a variety of settings. She is a past Chair of the Office of AIDS Research Advisory Council at the National Institutes of Health, Chair-elect of the HIV Medical Association, and previously served as an advisor to both the World Health Organization and the Joint United Nations Programme on HIV/AIDS.

Originally from Maryland, Dr. Walensky received her Bachelor of Arts from Washington University in St. Louis, her Doctor of Medicine from the Johns Hopkins School of Medicine, and her Masters in Public Health from the Harvard School of Public Health.

DEREK WALLACE, MBBS, Vice President and Global Dengue Program Head, Vaccine Business Unit, Takeda Pharmaceuticals

Derek Wallace, MBBS, is Vice President and Global Dengue Program Head at Takeda. In this role, he leads the global program team in the development of Takeda's dengue vaccine candidate (TAK-003). Mr. Wallace joined Takeda in September 2013 as Global Programme Medical Director responsible for the development of TAK-003 as well as Takeda's enterovirus vaccine candidate.

Mr. Wallace has over 16 years of experience in clinical development, infectious diseases and medical affairs. Prior to joining Takeda, he held clinical development and medical affairs positions at Merck, Novartis and Sanofi Pasteur. At Sanofi, Mr. Wallace served as clinical team leader for Sanofi's dengue vaccine candidate, influenza studies and preparations for first-in-human studies of vaccine candidates for malaria and meningitis B. His experience also includes transplant, cardiology and women's health.

Mr. Wallace holds a Diploma of Vaccinology from the Institut Pasteur and a Diploma in Pharmaceutical Medicine from University of Wales, Cardiff. He received his Bachelor of Medicine, Bachelor of Surgery from the University of Queensland.

MARY WOOLLEY, President and CEO, Research!America

Mary Woolley is the president of Research!America, an alliance that advocates for science, discovery, and innovation to achieve better health for all. Under her leadership, Research!America has earned the attention and respect of elected and appointed officials, researchers in the public, private and academic sectors, media, and community leaders with its record of innovation in advocacy for research. Research!America's reports and publications, websites, and constituent education initiatives have been honored by leading regional and international communications and advocacy organizations.

Woolley is an elected member of the National Academy of Medicine (formerly the Institute of Medicine) and served two terms on its Governing Council. She is a recipient of the Adam Yarmolinsky Medal for distinguished contributions to the mission of the Academy over a significant period. Woolley has served two terms on the National Academy of Sciences Board on Life Sciences, and currently serves on its Board for Higher Education and Workforce. She is a Fellow of the American Association for the Advancement of Science. She is a founding member of the Board of Associates of the Whitehead Institute for Biomedical Research. She is co-chair of the Science and Technology Action Committee. She has served as president of the Association of Independent Research Institutes (AIRI), on a number of academic boards and advisory councils, as a reviewer for the National Institutes of Health and National Science Foundation, and as a consultant to several research organizations.

She has a 30-year editorial and publication history on science advocacy and research related topics. Her op-eds and letters to the editor are published in newspapers and magazines from coast to coast including The New York Times and Washington Post. She has been published in Science, Nature, Issues in Science and Technology, The New England Journal of Medicine, The Journal of the American Medical Association, The Scientist, Women's Health Magazine and others. She is a sought-after speaker and is frequently interviewed by science, news and policy journalists and has received recognition by PBS as an "Unsung Heroine."

Woolley holds two honorary doctoral degrees, from the Northeast Ohio Medical University (NEOMED) and Wayne State University. For her work on behalf of medical research, she has been honored as a Woman of Vision by the American Committee for the Weizmann Institute of Science and has received the American Hospital Association Silver Touchstone Award for Public Affairs Programming, the Columbia University College of Physicians and Surgeons Dean's Award for Distinguished Service, the Federation of American Societies for Experimental Biology Special Award for Science Advocacy, the Friends of the National Institute for Nursing Research Health Advocacy Award, the Awareness and Advocacy Award from the Clinical Research Forum, the Friends of the National Library of Medicine Paul G. Rogers Public Service Award, the National Advocacy Leadership Award from the Lupus Foundation of America, and the AcademyHealth Chair Award.

A native of Chicago, Woolley received a bachelor of science from Stanford University and a master of arts from San Francisco State University. In her early career, Woolley served as San Francisco project director for the then largest-ever NIH-funded clinical trial, the Multiple Risk Factor Intervention Trial (MRFIT). In 1981, she became administrator of the Medical Research Institute of San Francisco, and in 1986 was named the Institute's executive director and CEO. Woolley has served as president and CEO of Research!America since 1990.

KEITH YAMAMOTO, PhD, Vice Chancellor for Science Policy and Strategy; Director, UCSF Precision Medicine; Professor, Cellular & Molecular Pharmacology, University of California, San Francisco

Dr. Keith R. Yamamoto is UCSF vice chancellor for science policy and strategy, director of precision medicine for UCSF, and professor of cellular and molecular pharmacology at UCSF. He is a leading researcher investigating transcriptional regulation by nuclear receptors, which mediate the actions of essential hormones

and cellular signals; he uses mechanistic and systems approaches to pursue these problems in pure molecules, cells and whole organisms. He has led or served on numerous national committees focused on public and scientific policy, public understanding and support of biological research, and science education; he chairs the Coalition for the Life Sciences, and sits on the National Academy of Medicine Council and the National Academy of Sciences Division of Earth and Life Studies Advisory Committee. As Chair of the NAS Board on Life Sciences, he created the study committee that produced “*Toward Precision Medicine: Building a Knowledge Network for Biomedical Research and a New Taxonomy of Disease*,” the report that enunciated the precision medicine concept, and he has helped to lead efforts in the White House, in Congress, in Sacramento and at UCSF to implement it. He has chaired or served on many committees that oversee training and the biomedical workforce, research funding, and the process of peer review and the policies that govern it at NIH. He is a member of the advisory board for Lawrence Berkeley National Laboratory and the board of directors of Research!America. He was elected to the National Academy of Sciences, the National Academy of Medicine, the American Academy of Arts and Sciences, and the American Academy of Microbiology, and is a fellow of the American Association for the Advancement of Science.

MICHAEL YBARRA, MD, Vice President of Advocacy and Strategic Alliances and Chief of Medical Affairs, PhRMA

Michael Ybarra, MD, FACEP, FAPCR is a board-certified emergency physician and Vice President and Chief of Medical Affairs at PhRMA. In his capacity at PhRMA, Dr. Ybarra leads stakeholder outreach on federal and international health policy issues and PhRMA’s internal and external medical affairs engagement. Dr. Ybarra continues to work clinically in the Emergency Department at MedStar Georgetown University Hospital.

CYNTHIA ZAGIEBOYLO, President and CEO, National MS Society

Cyndi Zagieboylo became president and CEO of the National MS Society in 2011. Her Society career started in 1985 and she has worked with every CEO of the organization including founder, Sylvia Lawry. Providing leadership on Pathways to MS Cures while empowering people affected by MS to live their best lives is her life’s work.

Cyndi is a founding member and executive committee chair of the International Progressive MS Alliance which was launched in 2013. The Alliance expedites the development of therapies for progressive MS and includes membership from 19 countries. She also serves on the MS International Federation Board of Trustees. She is passionate about building the MS movement, amplifying the voices of people affected by MS to influence lawmakers, and ensuring people affected by MS know that the National MS Society can be a supportive partner in their life journeys.

Cyndi received her bachelor’s degree in rehabilitation counseling and psychology from Springfield College and master’s degree in social psychology from the University of Connecticut.

ELIAS ZERHOUNI, MD, Professor Emeritus, Radiology and Biomedical Engineering, Johns Hopkins University; Director, National Institutes of Health, 2002-2008

Elias Zerhouni, MD, is Professor Emeritus Radiology and Biomedical Engineering, Johns Hopkins University, Baltimore, Maryland, USA. Dr. Zerhouni was most recently the President, Global Research & Development, and a member of the Executive Committee for Sanofi from January 2011 to July 2018. Dr. Zerhouni's academic career was spent at the Johns Hopkins University and Hospital where he was professor of Radiology and Biomedical engineering and senior adviser for Johns Hopkins Medicine. He served as Chair of the Russell H. Morgan Department of Radiology and Radiological Sciences, Vice Dean for Research and Executive Vice Dean of the School of Medicine from 1996 to 2002 before his appointment as Director of the National Institutes of Health from 2002 to 2008. In that position he oversaw the NIH's 27 Institutes and Centers with more than 18,000 employees and a budget of \$29.5 billion (2008). In November 2009, President Obama appointed Dr. Zerhouni as one of the first presidential U.S. science envoys. Dr. Zerhouni also served as senior fellow to the Bill and Melinda Gates foundation from 2009 to 2010 and senior advisor to the CEO of Sanofi. Dr. Zerhouni has founded or co-founded five start-up companies, authored more than 200 publications and holds several patents. He has assumed positions on several Boards, including most recently, the board of the Lasker Foundation, Research!America and the NIH Foundation. He is also a member of the U.S. National Academy of Medicine and the U.S. National Academy of Engineering. He received the prestigious Legion of Honor medal from the French National Order in 2008, and was elected in 2010 as a member of the French Academy of Medicine and appointed as Chair of Innovation at the College de France in 2011.



Thank You to Our Sponsors:

LEAD SPONSOR



FORUM PARTNER SPONSORS



ROUNDTABLE SPONSORS



FIRESIDE CHAT SPONSORS



FLASH TALKS SPONSOR



DAILY HOST



SPECIAL SPEAKER SERIES SPONSORS



WORKSHOP SPONSOR



ENVISION360 SPONSORS



Updated as of 9/10/21

The Research!America alliance advocates for science, discovery, and innovation to achieve better health for all.